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MRI DIFFUSION WEIGHTED IMAGING OF THE SPLEEN IN PATIENTS 
WITH CIRRHOSIS AND PORTAL HYPERTENSION. 
ABSTARCT 
Aim : 
ADC value of the diffusion weighted imaging is a measure of the perfusion of the 
organ. Portal hypertension (PH) is one of the essential manifestations of chronic 
liver disease. It was used in previous studies to assess indirectly assessing the 
fibrosis of the liver. However no studies have evaluated the ADC value of the 
spleen to assess the PH features in cirrhosis.  
We did a preliminary study  to find the difference in ADC mapping of normal and 
cirrhotic patients. Then we analyzed the correlation of ADC value of the spleen in 
cirrhotic patients, to the severity of PH in the form of clinically significant PH 
(CSPH) and also the surrogate markers of PH. 
 
Materials and Methods: 
We prospectively evaluated 51 patients with chronic liver disease/ cirrhosis  and 15 
normal liver function patients in our hospital from the month of June 2014 to 
September 2014 with DWI of the abdomen.Their clinical and laboratory 
parameters were noted. Using 1.5 tesla, diffusion weighted imaging with ADC 
mapping was performed with b value of 0, 300, 500 and the ADC value of the 
spleen and liver were calculated . They were correlated with the severity of the PH 
in terms of CSPH and PH surrogate markers. 
 
Results: 
We found significant difference between the ADC mapping of the spleen in normal 
and cirrhotic patients ( ADC of the spleen is increased in cirrhotics). In chronic 
liver disease / cirrhotic patients, we also found a significant correlation between 
ADC value of the spleen and CSPH, as well as PH surrogate markers in the form 
of grade of esophageal varices and symptomatic hypersplenism. However the ADC 
of the liver alone correlated significantly with the severity of liver diseases ( Child 
Pugh status and MELD)  
 
Conclusion : 
Our study showed that ADC value of the spleen correlated well with the severity of 
PH. ADC measurements may allow for noninvasive evaluation of portal pressure 
and even in assessment of treatment response. 
 
Keywords: Cirrhosis, Diffusion weighted imaging, Portal hypertension, Magnetic 
resonance imaging 
INTRODUCTION 
 Chronic liver disease is a major spectrum of disease due to various 
etiologies which deteriorates to cirrhosis in significant proportion of these 
patients. Cirrhosis is complicated by various clinical manifestations in the 
form of gastrointestinal bleed, ascites, hepatic encephalopathy, 
spontaneous bacterial peritonitis and hepatorenal syndrome. etc. Portal 
hypertension (PH) is an essential manifestation of end stage liver disease. 
It presents in the form of variceal bleed, hypersplenism and 
splenomegaly. However accurate evaluation of its severity depends on 
invasive investigations like repeated upper gastrointestinal endoscopy 
and hepatic venous wedge pressure monitoring. Non invasive 
investigations like ultrasound (US) abdomen and doppler, though simple, 
repeatable and cost effective, still it is plagued by its observer variations 
due to non standardized techniques and inferior cancer surveillance 
efficiency.1, 2  
 Recently, Magnetic Resonance Imaging (MRI) has been found to 
have superior safety and efficacy in evaluating severity of chronic liver 
disease patients and their cancer surveillance. 3, 4 Diffusion weighted 
imaging and MRI elastography was evaluated to assess the portal 
hemodynamics  and resistance  at the  liver  in chronic liver disease 
patients and found correlation to the degree of fibrosis. 5, 6 However very 
few studies have assessed the MRI characteristic of the spleen and its 
hemodynamics  in cirrhosis and  portal hypertensive patients. 7, 8 
RATIONALE FOR THE STUDY 
 Magnetic resonance imaging (MRI) has been used increasingly for 
the visualisation of anatomical changes in patients with cirrhosis. Further 
advancement in the form of diffusion-weighted imaging (DWI), has 
emerged as a promising imaging method for the noninvasive evaluation 
of liver fibrosis and cirrhosis. The principle of DWI involves measuring 
the Brownian molecular motion of water, thereby yielding the apparent 
diffusion coefficient (ADC) as a quantitative measure. 
 Apparent diffusion co-efficient (ADC) obtained using DWI is a 
useful parameter in assessing the relative hemodynamics of any organ. It 
is a measure of diffusion or perfusion calculated mathematically and 
reduced ADC appears as bright spot in DWI and it indicates restricted 
diffusion.9 
 Many series and reports have revealed that ADC is significantly 
reduced in cirrhotics compared to noncirrhotic livers.9 This is most 
probably related to the fibrosis and distortion of lobular architecture of 
the liver, which restricts water molecule motion. Also, these results have 
shown that ADC values are useful as a predictive marker of liver fibrosis, 
especially moderate and advanced stage of fibrosis. Differences in 
imaging technique and parameters are one of the main drawbacks, as 
ADC values vary significantly between different studies. Several authors 
have proposed to use the spleen as a reference organ for ADC 
measurements of liver parenchyma in order to decrease variability of 
liver ADC , even though in patients with cirrhosis and portal 
hypertension suffer from splenomegaly.10 Recently advances in MRI 
including, MR elastography observed that the spleen stiffness increase 
proportionately with the degrees of liver fibrosis and found a linear 
correlation between them.11 Possibly, this could be partly due to portal 
hypertension for this correlation. Hence, the grade of portal hypertension 
is a indirect prognostic factor for cirrhotic patients.  
 Similarly, cirrhosis is a state of hyperdymanic circulation and in 
view of portal hypertension, there is a splanchnic hyperemia. This 
splanchnic hyperemia is assessed by taking spleen as the representative 
organ of the splanchnic circulation. 12 Spleen ADC has been found to 
increase according to the different stages of cirrhosis. However the 
splanchnic hyperemia is the main contributor of portal hypertension in 
advanced cirrhosis and ADC value of the spleen should be a true 
reflection of the portal hypertension rather than the stage of cirrhosis. 
Portal hypertension necessarily need not correlate with the stages of 
cirrhosis. Hence we hypothesized that the ADC value of the spleen 
should be a reliable predictor of the severity of portal hypertension and 
should correlate well with the portal hypertension parameters in the form 
of grade of varices, gastrointestinal bleed, spleen size, platelet count, 
hypersplenism. etc. 13 
 
 
AIM OF THE STUDY 
PRIMARY OBJECTIVES 
1. To analyse the ADC value of the spleen in cirrhotic patients and to 
 compare with a control group with normal liver function test. 
2. To analyse the correlation of ADC value of the spleen in chronic 
liver disease patients, to the severity of portal hypertension in the 
form of clinically significant portal hypertension (CSPH) and also 
the surrogate markers of portal hypertension in the form of grade 
of esophageal varices,  incidence of gastrointestinal (GI) bleeds, 
hypersplenism and  size of the spleen. 
SECONDARY OBJECTIVES 
 To analyse the correlation of the spleen and liver ADC to the 
severity of cirrhosis in terms of Child Pugh’s status (CTP) and Model for 
End Stage Liver Disease (MELD) score. 
 
 
 
 
 
 
 
REVIEW OF LITERATURE 
 Cirrhosis was initially described in a 4th-century B.C hippocratic 
aphorism:  
 “In cases of jaundice it is a bad sign when the liver becomes hard”.  
Although the harmful effects of ethanol on the liver was 
appreciated by Galen and his contemporaries in 2nd century A.D, “liver 
disease due to alcoholism”, as a separate entity was first described by 
Baillie and other English writers in the 18th century after the “gin 
plague”.14 Shortly thereafter, Laënnec coined the term cirrhosis, which 
got derived from the Greek word kirrhos, meaning “orange-yellow.” In 
19th century, many European and English pathologists were analyzing 
this topic, including Carswell and Rokitansky, who described the gross 
and histopathologic characteristics of the disease.  
ETIOLOGY OF CIRRHOSIS 
 Cirrhosis is the end result of an insult, hepatocellular injury caused 
by various etiologies which includes toxins, viruses, cholestasis, 
autoimmune, and genetic disorders (metabolic) (hemochromatosis, 
Wilson's disease, α1-antitrypsin deficiency). Recently, Non alcoholic 
steatohepatitis (NASH) is very much prevalent in India. 
 Figure 1:  Etiology of cirrhosis 
 Although the mechanisms by which these etiologies are different, 
the end pathologic response is the same: “hepatocellular injury followed 
by fibrosis and regeneration”. However in clinical situations, each of 
these elements can exist alone “necrosis, uncomplicated hepatitis; 
fibrosis, congenital hepatic fibrosis; nodular regeneration, partial nodular 
transformation”, but the presence of “all three are required for the 
development of cirrhosis”. Cirrhosis is a diffuse pathology and can be 
classified either by etiology or morphologically. Posthepatitic cirrhosis 
especially due to viral etiology, which is generally macronodular and 
ethanol related cirrhosis, which is usually micronodular, were the two 
most common etiologies in the world. Few occasions the cause of the 
hepatocellular injury cannot be discerned as the pathologic responses to 
these injuries are the same. They are named as cryptogenic cirrhosis. 
  
PATHOPHYSIOLOGY OF CIRRHOSIS 
 
Figure.2: The pathophysiology of complications of cirrhosis 
 Cirrhosis exhibits two major clinical manifestations: 
“hepatocellular failure and portal hypertension”. Even though the 
noxious stimuli is removed from the patient (e.g., alcohol abstinence), the 
hepatocellular may keep on progressing and results in cirrhosis. Although 
the mechanism is not clearly understood, they can be related to ischemia, 
secondary to the diffuse fibrosis especially along the portal tract, 
intrahepatic and extrahepatic shunts. Autoimmunity can also play a role. 
Finally in view of the periportal fibrosis and perisinusoidal involvement, 
the hepatic architecture is distorted and simultaneously cause increased 
hepatic vascular resistance, resulting in portal hypertension and its 
clinical complications such as variceal bleed, hepatic  encephalopathy, 
volume overload, and hypersplenism. 
 Figure 3: Course in a chronic liver disease patient. 
 Historically, cirrhosis was managed palliatively with the treatment 
of portal hypertension complications rather than cirrhosis per se. 
However, since 1966, after the invention of liver transplantation, which is 
the definitive treatment modality for cirrhosis, the management of 
chronic liver disease has been highly effective, with most of them having 
long-term survival (70%).15 It is the optimal use of the palliative 
management initially in managing these patients medically and then 
deciding on the definitive management (liver transplantation) once the 
risk for death is more is the challenge of managing these patients.  
 
IMPLICATIONS OF  LIVER DISEASES IN INDIA 
 According to recent survey, liver diseases affect almost one of 
every 10 Indians. The rising trend of these problems in India is related to 
the increased prevalence of obesity and diabetes epidemic. As a result of 
these, there has been an emergence of a recent entity called as non 
alcoholic related steatohepatitis which resulted from fatty liver in 10% of 
these patients. 16 This forms a major cause of cirrhosis in India along with 
viral infections (Hepatitis B and C), apart from alcohol intake. According 
to the recent WHO report released in April 2011, Liver Disease related 
deaths in India reached 2 million or 2.3% of the total deaths. Most 
common cause of death in cirrhosis is hepatic failure, followed by 
variceal hemorrhage and decompensation. 
MANIFESTATIONS OF CIRRHOSIS 
 A number of physical findings have been described in patients with 
cirrhosis. They are broadly classified as features of hepatic cell failure or 
because of portal hypertension. They are schematically described in the 
diagram shown below.(Fig.4)                                               
 Figure 4: Presentation of cirrhosis and portal hypertension. 
ANATOMY, PHYSIOLOGY OF PORTAL HYPERTENSION  
 The liver is a peculiar organ in that it has a two blood supply 
through  portal vein and hepatic artery.17 
PORTAL VEIN 
 The main portal vein is formed behind the neck of the pancreas at 
L2 level by the confluence of the splenic and superior mesenteric vein. It 
measures about 60 to 80 mm in length and 9- 10mm in diameter (Fig.5). 
The left coronary or gastric vein drains the distal oesophagus and lesser 
curvature of the stomach, and empties into the portal vein just before its 
formation. The inferior mesenteric vein drains the distal part of the colon 
and drains into the splenic vein which course posteriorly to the distal part 
of the pancreas and joins the superior mesenteric vein.  
 Figure 5: The portal venous circulation 
HEPATIC ARTERY 
 The hepatic artery takes its origin from celiac axis along with 
splenic and left gastric and course to the left of the bile duct in the 
hepatoduodenal ligament before it enters the liver.  
REGULATION OF BLOOD FLOW 
 Liver blood flow approximates 1.5 L/min, which forms about 25% 
of the total cardiac output. The portal flow contributes to 70% of the total 
liver blood flow, whereas hepatic artery contributes to the main oxygen 
supply of the liver (> 50%).17 
 The splanchnic circulation is modulated by various vasogenic 
factors. The volume of splanchnic venous flow is indirectly regulated by 
vasoconstrictors and vasodilators of the splanchnic arterial bed. However, 
the hepatic arterioles are directly regulated by the circulating 
catecholamines from the sympathetic nervous stimulation. There is an 
autoregulatory system between the hepatic artery and portal circulation 
called as arterial buffer response, which is the modulation of the hepatic 
arterial blood flow inversely proportional to the portal blood flow. This 
response is very critical in situations of intense vasoconstriction such as 
in shock or disease related or surgically diverted shunts. This response 
maintains the optimal blood flow to the liver and maintains the functions 
of the liver.18 
PATHOPHYSIOLOGY OF PORTAL HYPERTENSION 
 
Figure 6: Pathophysiology of the mechanism of portal hypertension. 
 The mechanism behind the effects of portal hypertension is 
because of two factors.(fig.6) Initially it is the increased resistance to the 
portal venous blood flow at various levels in the portal circulation, 
thereby classified according to the site of obstruction. However, in 
addition to the elevated passive resistance due to  portal fibrosis and 
regenerative nodules, increased vascular resistance at these levels due to 
active vasoconstriction caused by various agents like endothelin, 
norepinephrine, and other  humoral factors contribute significantly to the 
increased vascular resistance.18 
 However in the late stages of the chronic liver disease especially in 
cirrhosis, it is the increased portal blood blow due to the hyperdynamic 
systemic circulation due to splanchnic hyperemia and this is the 
predominant contributor for sustaining portal hypertension.19 The 
etiology for this hyperdynamic circulation with increased cardiac output 
and splanchnic hyperemia was not known. However it is the splanchnic 
hormones, like glucagon, and reduced sensitivity of the splanchnic 
vascular bed to catecholamines which might play a role. Elevated 
production of Nitric oxide and prostacyclins by vascular endothelium 
may also contribute to this.  
CLASSIFICATION OF  PORTAL HYPERTENSION 
 According to the level of resistance, the etiologies of portal 
hypertension have been classified as prehepatic, intrahepatic and 
posthepatic etiologies. 
 Table 1: Anatomical classification of portal hypertension 
PREHEPATIC PORTAL HYPERTENSION  
 The most common cause of prehepatic portal hypertension which 
is predominant in children is the extrahepatic portal vein obstruction. 
This approximates for almost 50% of cases of PH in children. When the 
main portal vein gets occluded in the absence of chronic liver disease, 
collateral vessels will develop over the hepatoduodenal ligament to 
restore the portal flow to the liver (hepatopetal flow) in order to restore 
portal perfusion. This transformation is termed as cavernomatous 
malformation of the portal vein. 20 Apart from portal vein, when splenic 
vein alone gets thrombosed as secondary to pancreatic neoplasm or 
inflammation, which is called as left-sided or sinistrial portal 
hypertension, it results in gastrosplenic segment venous pressure 
elevation with rest of the splanchnic system with normal portal pressures. 
Here, the left  gastroepiploic vein forms the major collateral and thereby 
they develop gastric rather than esophageal, varices. This is important to 
diagnose because, this variant of portal hypertension can be easily treated 
with splenectomy itself rather than any other shunt surgeries.  
INTRAHEPATIC PORTAL HYPERTENSION 
 The level of increased resistance in the intrahepatic portal 
hypertension can be at  
1. Presinusoidal 
2. Sinusoidal, or  
3. Postsinusoidal level.  
 Occasionally, more than one level can be involved.  
PRESINUSOIDAL 
 Though it is rare in India, the most common cause of presinusoidal 
portal hypertension worldwide is schistosomiasis parasitic infestation. In 
India, non cirrhotic portal fibrosis is the most common reason which 
results in presinusoidal portal hypertension. This is due to either infection 
or autoimmunity. 
SINUSOIDAL 
 This is the most common form of portal hypertension in adults. 
Ethanol and viral hepatitis are the most common cause of portal 
hypertension in the India. As earlier mentioned they cause increased 
resistance at two levels 
1. Sinusoidal - due to collagen deposit in the extracellular 
matrix, especially in the space of Disse and 
2.  Postsinusoidal - due to regenerating nodules distorting small 
hepatic venules. 
POSTSINUSOIDAL 
 Postsinusoidal etiologies of portal hypertension are not common as 
sinusoidal and they include etiologies which affect the hepatic veins or 
the inferior vena cava causing congestion and portal hypertension.  
1. Budd-Chiari syndrome (Inferior vena cava or hepatic vein or 
both thrombosis),  
2. Constrictive  pericarditis,  and heart failure are  the  most  
  common causes. 21 
 Rarely, increased portal blood flow alone, due to huge 
splenomegaly (idiopathic portal hypertension) or a Porto arterial fistula 
can cause portal hypertension. 
 
PORTOSYSTEMIC COLLATERALS 
 Portal pressure of more than 5 mm Hg is defined as portal 
hypertension. Portosystemic collaterals develop when portal pressure 
increases to the range of 8-10 mm Hg. It is well known that collateral 
vessels develop in places where portal and systemic venous circulations 
are in close proximity. Examples are in the distal esophagus, fundus of 
stomach, umbilicus and distal aspect of rectum. (Fig. 7 ).  
 
 
Figure 7:  Portosystemic collaterals 
 Clinically, the most relevant site of porto-systemic collateralization 
is between coronary and short gastric veins of portal system and the 
azygos venous system. Collateralisation in this site results in formation of 
esophagogastric varices. (Fig.8) 
 
Figure 8: Endoscopic appearance of esophageal varices. 
 Other well known sites of portosystemic collateralization include 
recanalized umbilical vein from the left portal vein to the epigastric 
venous system (caput medusae), retroperitoneal collateral vessels, and the 
hemorrhoidal venous plexus. Intrahepatic shunts due to capillarization of 
hepatic sinusoids also form a significant channel of portosystemic 
shunting. All these factors result in reduction in portal flow through the 
liver. This leads to increase in hepatic arterial flow to liver. This is 
termed hepatic artery buffer response. 
 
PORTAL HYPERTENSION- IMPLICATIONS 
 Most of the clinical manifestations of advanced liver disease are 
due to portal hypertension. These are gastrointestinal bleeding from 
esophageal or gastric varices, portal hypertensive gastropathy and 
colopathy, hyperdynamic circulation, ascites, hypersplenism and 
hepatorenal syndrome. Some complications of advanced liver disease like 
spontaneous bacterial peritonitis, hepatic encephalopathy and 
hepatopulmonary syndrome are multifactorial, but portal hypertension 
still plays a major role in their pathophysiology. 
 Normal hepatic venous wedge pressure is 3-6 mmHg. Ascites 
forms when the pressure is about 8 mm Hg and varices form when 
pressure is about 12 mm Hg. The most common and life threatening 
complication of portal hypertension is variceal bleed from esophago-
gastric varices. This results in upto one-third of all deaths due to 
cirrhosis. Uncontrolled bleeding causes death in about a half of patients 
with bleeding esophageal varices. Rest of the patients die due to liver 
decompensation that invariably follows an episode of major variceal 
bleeding. Majority of patients with cirrhosis will develop esophageal 
varices (90%).22 About a third of them will develop bleeding and one 
third to one half of patients with bleeding varices die during the first 
episode of bleeding.  
 Ascites occurs commonly in patients who develop significant 
sinusoidal portal hypertension. Reduction in portal pressure by surgically 
constructed porto systemic shunts or radiologic shunts like TIPSS 
(Transjugular Intrahepatic Portosystemic Shunt) leads to resolution or 
ease in control of ascites.23 This is the proof of concept that portal 
hypertension is the causative factor for ascites. 
 Hypersplenism is another important effect of portal hypertension. 
Here, there is reduction in one or more blood cell lines in peripheral 
blood along with an overactive bone marrow. The most common cell line 
affected is platelets and this results in thrombocytopenia.19 Mechanism of 
cytopenias in hypersplenism is sequestration of blood in enlarged spleen. 
It also is accentuated by immunologic mechanisms and intravascular 
activation of platelets. Banti first described the peripheral blood picture 
associated with hypersplenism in the setting of cirrhosis and a large 
spleen. Hypersplenism occurs in non cirrhotic causes of portal 
hypertension like non cirrhotic portal fibrosis and extrahepatic portal vein 
obstruction. The latter fact proves that hypersplenism is merely due to the 
presence of portal hypertension and can occur in the absence of liver 
disease.  
 The outcome of patients with cirrhosis is influenced by many 
factors like the etiology of cirrhosis, severity of portal hypertension, 
presence of comorbid conditions and complications of liver disease. 
There are several prognostication models for predicting outcome of 
cirrhosis. Child-Pugh score(CTP), described initially to predict outcome 
of shunt operation in patients with cirrhosis is one of the earliest 
described methods. It still remains a very useful method to prognosticate 
patients with liver disease. Model for end stage liver disease (MELD) 
score is another commonly used prognostic model and uses a 
combination of serum bilirubin, serum creatinine and international 
normalized ratio (INR) of the patient in question. MELD score predicts 
the 3 month probability of death in patients with cirrhosis. The following 
table shows the parameters and their use to calculate the “Child-Pugh 
score and the mathematical formula used to calculate MELD score.  
Table 2 :Child-Pugh Criteria for Hepatic Functional Reserve 
Clinical and laboratory 
measurement 
1 2 3 
Encephalopathy (grade) None 1 or 2 3 or 4 
Ascites None Mild Moderate 
Bilirubin (mg/dL) 1-2 2.1-3 ≥3.1 
Albumin (g/dL) ≥3.5 2.8-3.4 ≤2.7 
Prothrombin time (increase, s) 1-4 4.1-6 ≥6.1 
 
Grade A, 5-6; grade B, 7-9; grade C, 10-15 
  
MELD = 3.8[Ln serum bilirubin (mg/dL)] + 11.2[Ln INR] + 9.6 
[Ln serum creatinine (mg/dL)]+6.4  
where Ln is the natural logarithm.” 
DIAGNOSIS OF PORTAL HYPERTENSION AND CIRRHOSIS 
 Chronic liver disease is a heterogeneous and dynamic condition. 
The exact estimations of the stage and the changes in hepatic fibrosis and 
PHT are essential in the management of patients with this disease. 
 Portal hypertension is an essential event in the progression of 
chronic liver disease when severe fibrosis or cirrhosis develops. 24Once 
the portal pressure increases above 10 mmHg it is termed as clinically 
significant portal hypertension – CSPH, where the risk of developing 
portal hypertension related complications like variceal bleed or ascites 
are high. However it is very difficult to estimate this pressure gradient 
non invasively. Histopathological examination of the liver biopsy 
samples has been practically considered as the gold standard for assessing 
the stage and severity of liver fibrosis and for diagnosing cirrhosis. 
However, it is the invasive nature of this investigation was the major 
limiting factor in its use. And also sampling error has been seen 
frequently with liver biopsy, especially wedge biopsy and trucut biopsy. 
Over the last two decades, various studies have been done to circumvent 
these problems and have tried to invent non-invasive techniques to 
evaluate liver fibrosis and cirrhosis along with portal hypertension.24 
These have been possible after the invention of various non invasive 
investigations like ultrasound with Doppler, computer tomography, 
magnetic resonance imaging etc.  
 The ideal test for assessing liver fibrosis and cirrhosis along with 
portal hypertension is the one which has to be harmless, easy to do, not 
expensive, repeatable (between patients and between and within labs). It 
should give an accurate estimate of the different stages of liver fibrosis 
from the pre-cirrhotic stage, and early cirrhosis. Also these tests should 
have a prognostic significance on the prediction of future problems like 
variceal bleed, hepatic decompensation and most importantly the stage 
for the requirement of transplantation, and mortality. 
PHYSICAL EXAMINATION 
 The simplest, cheapest and easily available method which can be 
repeated many times to get information on the diagnosis and staging of 
cirrhosis and/or of portal hypertension is the routine clinical examination 
There are lots of clinical stigmata of decompensated liver disease which 
are helpful in confirming advance stage of chronic liver disease. They are 
a firm to hard left hepatomegaly , gynecomastia, atrophy of the testes, 
parotid enlargement, features of hepatic dysfunction like yellowish 
discolouration of the sclera, urine, angio malformations such as spider 
naevi, leuconychia, palmar erythema or altered sensorium, visualization 
of parietal wall collaterals, volume overload in the form of ascites, pedal 
oedema and splenic enlargement. Splenomegaly is considered as the most 
important stand alone physical diagnostic marker of portal hypertension. 
In view of the increased cardiac output and hyperdynamic circulation, 
they can present with peripheral vasodilatation, reduced blood pressure 
and increased pulse rate. These are signs of advance liver diseases. All 
these clinical signs and symptoms are found in end stage liver disease and 
they in association are very specific to this syndrome. Portal hypertension 
usually presents with variceal bleed  mostly esophageal or non 
esophageal bleed, ascites and presence of splenomegaly and large 
abdominal wall collaterals. In a latest study, where patients with early 
compensated chronic liver disease were evaluated with hepatic venous 
wedge pressure gradient (HVPG) and correlated with their clinical signs 
and symptoms, they found none of them correlated well with HVPG > 
10mm Hg.  However, the presence of vascular malformations like spider 
naevi was found to be predictive of oesophageal varices but not their 
bleeding. 
LABORATORY EXAMINATION 
 Various indirect serum markers of fibrosis has been evaluated like 
indicators of hepatocyte damage (AST, ALT), impaired bile secretion 
(γGT, bilirubin), synthetic function markers of hepatocytes (i.e. 
cholesterol, INR, ApoA1, N-glycans, haptoglobin), and hypersplenism 
due to splenomegaly (i.e. platelet count). Though in a recent evaluation 
by meta-analysis, none of these markers helps in differentiating various 
levels of fibrosis and severity of portal hypertension. In a recent study, 
serum hyaluronic acid (HA) has been found to have a prognostic  value 
equivalent to CTP score for the prediction of mortality and cirrhosis 
complications.25 
 For portal hypertension, CTP score and its objective factors 
(albumin, bilirubin, INR) correlated well with HVPG. In addition the 
CTP score correlated well with the severity of portal hypertension in the 
form of grade of oesophgeal varices and their occurrence in cirrhotic 
patients. As expected, this correlation is also found in early cirrhotic 
patients with no history of decompensation, impling that a significant 
correlation exists between the architectural distortion and the onset of 
portal hypertension and ultimately, hepatocellular failure.  
Platelet count, which is an important component of hypersplenism 
has been found to correlate independently with the prevalence, grade of 
oesophageal varices in various studies. This suggests its correlation with 
severity of portal hypertension and in another study, platelet count to 
spleen diameter ratio > 909  was found to have  100% negative predictive 
value for presence of esophageal varices.26 The author emphasis that it 
can help in avoiding unnecessary endoscopy.  
IMAGING OF CIRRHOSIS AND PORTAL HYPERTENSION 
 In chronic liver disease, the imaging diagnosis plays several 
significant roles in patient management, both in terms of diagnosing 
hepatocellular carcinoma and predicting its progression to cirrhosis. The 
basic diagnostic imaging modalities consist of ultrasound (US), computed 
tomography (CT), and magnetic resonance (MR) based methods, and 
many specific techniques derived from these basic methods are currently 
being developed to achieve convenient, non-invasive, and accurate 
diagnosis. 
ULTRASOUND AND DOPPLER-ULTRASOUND 
 Ultrasonography is an inexpensive and harmless technique which 
can be used as an initial evaluation for the diagnosis and follow-up of 
liver diseases. US with Doppler were very accurate in diagnosing flow 
related issues in portal and hepatic veins.27 Hence, it has the advantage of 
non invasively evaluating a portal hypertensive patient and finding out 
the location of the thrombosis, thereby identifying the causes, 
extrahepatic portal vein obstruction , Budd Chiari syndrome and isolated 
splenic vein thrombosis. It is advantageous over liver biopsy in terms of 
non invasiveness, available at all centres, multiple times repeatable, can 
focus on all the areas of liver especially in Budd Chiari syndrome where 
there is difference in the liver biopsy taken from obstructed hepatic 
segment and non obstructed hepatic segment.2 
 Conventional US looks out for the morphological changes of the 
liver in cirrhosis and the evidence of portal hypertension (Table 2). 
Conventional US findings are highly specific, in that the findings of 
cirrhosis can “rules-in” cirrhosis with positive predictive value. They are 
enough for the establishment of liver disease like cirrhosis. Even then, it 
cannot differentiate early non shrunken cirrhosis with non cirrhotic portal 
fibrosis and Budd Chiari syndrome. In contrast on evaluating a patient 
suspected of liver disease, no individual US findings has good negative 
predictive value, impling that a negative finding cannot fully rule-out 
cirrhosis. 
 The best accurate single US sign for establishing the diagnosis of 
cirrhosis, is by assessing the liver morphology. Nodularity of the liver 
surface can be found in early stages of cirrhosis and its has a high 
predictive value.28 With the use of high frequency abdominal US probes, 
diagnostic accuracy has got increased over the conventional  US probes, 
and should be preferred.29 (Fig.10) 
 Figure 10: Conventional US abdomen showing nodular liver with 
ascites suggestive of cirrhosis 
In a recent study, the predictive value of combining nodular liver 
morphology with main portal vein velocity < 12 cm/s (mean) was about 
80% in  discriminating chronic hepatitis C virus patients with severe 
grade of fibrosis  and those with cirrhosis.30 In patients, clinically 
suspicious of cirrhosis , the detection of nodular liver morphology is an 
excellent method to “rule in” cirrhosis, and then by combining this with 
transient elastography (TE) favours the best diagnostic performance .30-32 
 
 Figure 11: Colour doppler shows normal portal venous spectral 
waveform. 
 
 
Figure 12: Colour doppler shows bidirectional flow in portal vein. 
  
Figure 13: Colour doppler demonstrating hepatofugal flow in 
the main portal vein in advanced cirrhosis. 
 
 
 
Figure 14:  Colour doppler shows splenorenal collaterals. 
 
 Figure 15: Doppler US- showing in the sagittal paramedian 
view, the flow in the coronary vein (CV) is directed superiorly and 
away from the splenic vein 
 
Figure 16: Doppler US- showing in the sagittal view slightly 
posterior, the tortuousity of the CV as it extends to the 
gastroesophageal junction 
 Figure 17: Doppler US, showing in the longitudinal view of the left 
liver lobe, the gastroesophageal collaterals close to the diaphragm 
 
Figure 18:  Ultrasonography of the spleen showing Gandy gamma 
bodies in congestive spleen 
 Similarly to the diagnosis of cirrhosis with US, all ultrasound signs 
of portal hypertension are very specific, though their sensitivity is low, 
especially in early cirrhosis. Hence the presence of an ultrasound sign or 
a combination of multiple signs can accurately “rules-in” portal 
hypertension. However the same signs absence cannot defer the 
diagnosis. Out of all the US signs for portal hypertension, the 
measurement of spleen enlargement is the most common sign to be 
correlated well with the presence and severity of portal hypertension.33 
Their sensitivity is high as proven in various studies, though their 
specificity value falls to 50–80% in  different series. It is an independent 
predictor of oesophageal varices, and is associated to clinically 
significant PH in patients with early and compensated cirrhosis.34 
 
Figure 19: Portal venous velocity measured with Doppler US 
(10.7 cm/s) in a patient with cirrhosis. 
 
 Figure 20: Doppler US showing change in the hepatic vein 
waveform and damping index (A) before and (B) 3 month after 
propranolol treatment in a patient with liver cirrhosis 
 On analyzing the various signs of US for its correlation to the 
severity of  PH (CSPH) , the presence of patent paraumbilical vein, large 
collateral between left renal vein and splenic vein, dilated and tortuous 
left coronary and short gastric veins,  and the reversal of flow in the 
portal circulation were 100% specific US signs of CSPH.35 Other US 
signs of CSPH include 
1.  Dilatation of main portal vein (> 13mm in diameter) 
2.  Absence or reduced respiratory variations of splenic and 
SMV diameter  
3  Decreased portal vein mean velocity (< 10–12 cm/s and < 16 
cm/s ,mean and maximal velocimetry of main portal vein 
flow, respectively) 
 4.  Elevated congestive index of main portal vein  
5.  Distorted hepatic venous Doppler pattern 
 6.  Elevated intraparenchymal splenic and hepatic artery 
resistance (impedence) 
 7.  Elevated intraparenchymal renal artery impedance and 
reduced SMA impedance  
 HVPG, which is the gold standard for the portal hypertension 
correlated significantly with few US parameters like main portal vein 
mean velocity and volume of portal blood flow, hepatic artery RI 
(resistive index), splenic and renal artery resistance and pulsatility index.  
 However the degree of correlation between these factors is only 
mild to moderate and these US signs cannot replace or can apply as 
useful surrogates for HVPG. Some Doppler signs hold prognostic value 
in cirrhotic patients. 
PREDICTORS OF VARICEAL BLEED 
 Like the diagnosis of oesophageal varices and variceal formation, 
their growth and the risk of bleeding, models for the prediction of varices 
of any size or of large varices involves main portal vein diameter or 
spleen dimension in association with laboratory tests (platelet count and 
INR). This was evaluated in few prospective studies in early cirrhosis 
which found a good discriminating ability.35 However, later studies could 
not validate these parameters for the accurate prediction of varices.  
1.  Porto-systemic collaterals such as left coronary vein > 3 mm 
and short gastric vein (collaterals at superior spleen half) 
reliably suggest the prevalence of oesophageal varices, and 
their growth/increase in size have been associated with a 
increased  proportion of variceal formation and growth.36 
2.  Progressive splenomegaly can predict variceal formation and 
growth . 
3. In a prospective study, congestive index of the main portal 
vein (ratio between the cross-sectional area and portal flow 
velocity) predicts the first variceal bleed in patients with 
varices . 
As for the prediction of first clinical decompensation of any kind, 
progressive splenomegaly (> 1 cm) on follow up scan might be 
correlating with a higher possibility of developing the first clinical 
decompensation of cirrhosis. A main portal vein mean velocity > 15 cm/s 
was the only sign independently predictive of increased risk of non-
malignant PV thrombosis in a prospective study. 
 Ultrasound is highly accurate in diagnosing and estimating ascites, 
which is the most common clinical manifestation of decompensated 
cirrhosis and it holds a severe prognostic significance. The elevation of 
intrarenal arteriolar RI in patients with end stage liver disease is related to 
arterial vasoconstriction (Renin Angiotensin mechanism). It is found in 
approximately two fifth of patients with ascites and efficacious in 
diagnosing HRS (hepato-renal syndrome). A shrunken liver, 
splenomegaly of > 14.5 cm, mean main PV velocity > 10 cm/s and loss 
of pulsatile pattern ( triphasic  biphasic monophasic) of hepatic veins 
have been correlated to higher mortality on follow-up in patients with 
early cirrhosis. 
Contrast-enhanced ultrasound (CEUS) 
 CEUS imaging represents a new US modality for the assessment of 
chronic liver disease.37 Hepatic vein transit times (HVTT) have been 
shown to be reduced with worsening liver disease. HVTT showed a 
significantly strong correlation with PHT and the AUROC of HVTT for 
the diagnosis of clinically significant PHT was 0.973.38 However, this 
method also has some limitations, such as the requirements for the 
injection of a contrast agent, considerable operator skill, and access to the 
relevant technology.39, 40 “More intensive studies and validation are 
needed. 
 
 
 
  
US signs of cirrhosis 
  Sensitivity Specificity 
Liver 
Nodular liver surface 55–91% 82–95% 
Coarse echopattern 
20% overall 
51% HBV-
HDV 
90% 
Left lobe/ right lobe ratio 
> 1.30 
74% 
 
100% 
Caudate lobe/ right lobe 
ratio ≥ 0.65 (hypertrophy 
of caudate lobe) 
43–84% 100% 
Reduction of the medial 
segment of left hepatic 
lobe 
74% 100% 
Hepatic 
veins 
Narrowing and loss of 
normal phasicity of flow 
by Doppler 
Not reported Not reported 
Altered straightness 97% 91% 86% 
Nonuniformity of hepatic 
vein wall echogenicity 
88%  
Hepatic  
artery 
Increased diameter Not reported Not reported 
 
US signs of portal hypertension 
  Sensitivity Specificity 
 Portal 
venous 
system 
Dilatation of 
portal vein (≥ 13 
mm) 
< 50% 90–100% 
Reduction of 
portal vein blood 
flow velocity 
(Max vel < 16 
cm/s;) 
80–88% 80–96% 
Mean vel < 13 cm/ 
s 
  
Inversion of portal 
vein blood flow 
Not reported; 
sign prevalence: 
8.3% of 
unselected pts 
100% 
Increased portal 
vein congestion 
index (≥ 0.08) 
67–95% 100% 
Dilatation of 
splenic vein (SV) 
and superior 
mesenteric vein 
(SMV) (≥ 11 mm) 
72% 100% 
Reduction of 
respiratory 
variation of 
79.7% 100% 
US signs of portal hypertension 
  Sensitivity Specificity 
diameter in SV or 
SMV (<40%) 
Spleen 
Splenomegaly 
(diameter > 12 cm 
and/or area ≥ 45 
cm2 
93% 36% 
Splenic 
artery 
Increased resistive 
index of the 
intraparenchymal 
branches ( ≥0.60) 
84.6% 70.4% 
Hepatic artery 
Increased resistive 
index of artery at 
the porta hepatis 
(> 0.78) 
50% 100% 
Renal 
artery 
Increased resistive 
index of the right 
interlobar renal 
artery 
79.5% 59.3% 
SMA 
Decreased 
pulsatility index 
(≥ 2.70) 
85.7% 65.2% 
Presence of porto-systemic collateral 
circulation 
83% 100% 
 
COMPUTED TOMOGRAPHIC SCAN (CT) and MRI  
 Cross-sectional imaging studies such as CT and MRI are useful 
imaging modalities for the diagnosis of cirrhosis. These modalities are 
considered to be standard methods for the diagnosis of HCC on the 
background of chronic liver disease, including cirrhosis. The radiologic 
features of advanced cirrhosis are normally obvious and include surface 
nodularity, prominent fibrous  septa, shrinkage of liver volume, and an 
enlarged portal venous system including varices and splenomegaly due to 
PHT. 41However, it is difficult to diagnose the early stage of cirrhosis. As 
such, various functional techniques using CTand MRI have been 
developed recently and described in many hepatology and radiology 
journals.42 
 However, in the era of multidetector CT, which enables CT 
scanning at a submillimeter thickness, CT can be used to obtain 
information not only about the cirrhotic liver itself but also about the 
PHT caused by cirrhosis. Various portosystemic collateral veins can also 
be depicted in the CT scan, and physicians can plan a strategy for the 
treatment of varices, including the insertion of a transjugular intrahepatic 
portosystemic shunt and balloon-occluded retrograde transvenous 
obliteration. Moreover, as with endoscopy, demonstrating the presence of 
esophageal and gastric varices is now possible using CT. The sensitivity 
and specificity of CT were found to be 96% and 55%, respectively, to 
detect esophageal varices and 93% and 80%, respectively to detect high-
risk esophageal varices.43 Using the 1-to 3-mm multiplanar reformat or 
surface-shaded display can also increase the specificity of CT for the risk 
stratification of esophageal varices. With regard to gastric varices, the 
sensitivity and specificity were 83%-89% and 75%-79%, respectively.44 
Although these results are not bad, the accuracy for small varices remains 
low. 
 
 
 
Figure 21: Contrast enhanced CT showing evidence of 
cirrhosis with nodular liver surface and also portal hypertension 
with a patent paraumbilical vein  and spleen enlargement. 
 Figure 22:  Contrast enhanced CT images (axial and coronal) 
showing shrunken nodular liver with tortuous gastro-esophageal 
collaterals and gross splenomegaly. 
 Figure 23: Contrast enhanced CT coronal images showing dilated 
left coronary vein and forming large oesophageal collaterals 
 
Figure 24: Contrast enhanced CT axial MIP images showing 
the spontaneous splenorenal collaterals between splenic and left renal 
vein. 
Few large studies have analysed the efficacy of CT, either single 
detector or multidetector scanning in the assessment of the oesophageal 
varices in cirrhotic patients. They found CT are reliable in diagnosing 
large oesophageal varices with specificity (91–100%) and sensitivity (85–
100%), though with some inter-observer variations.45 However, their role 
or accuracy in diagnosing smaller varices is significantly reduced and 
they are not recommended for these varices. In a recent study done to 
analyse the cost-benefit ratio showed that direct computer tomography 
screening of oesophageal varices was more benefitting than endoscopic 
visualization and that computer tomography followed by endoscopic 
visualization is helpful for cirrhotic patients with few small varices 
visualized or suspected on CT .46 
 Dynamic imaging with contrast CT and MRI imaging (hepatic 
contrast images after administration of gadolinium chelate and 
compartmental analysis of intensity versus time curves for MRI images), 
and phase contrast MR venography helps in the quantitative assessment 
of the flow in the portal vein and azygous venous system. The importance 
of assessing azygous venous flow is that it is an indirect predictor of the 
grade of lower oesphageal porto-systemic collateral flow. 47-50Azygous 
venous flow, as measured by phase contrast MR venography, was 
associated well with the presence of oesophageal varices at endoscopy. It 
also predicts the risk of variceal bleeding with increased accuracy. Other 
parameters like portal venous proportion of the hepatic perfusion and the 
average transit time in MRI has been found to have a significant 
correlation with the hepatic venous wedge pressure in a recent study. 
However, whether any of these highly expensive and sophisticated 
techniques gives more information, in addition to the physical, 
biochemical, ultrasound or TE parameters has to be evaluated in further 
studies. 
 
Figure 25:  MRI axial image shows a nodular surface liver with 
splenomegaly and enlarged left liver and edematous  gallbladder 
fossa (asterisk), notching of the right lobe (arrow). 
 Figure 26: Postcontrast T1 weighted MRI abdomen shows 
varices in the fundus of the stomach. 
 
Figure 27: MRI postcontrast T1W shows paraesophageal 
collaterals projecting outside the oesophagus. 
 
 Figure 28: MRI abdomen shows hypointense gammagandy 
nodules diffusely scattered in spleen in portal hypertension. 
 Figure 29:Algorithm for clinical suspicion of cirrhosis with 
 portal hypertension 
NON INVASIVE ASSESSMENT OF LIVER FIBROSIS 
 Regardless of its underlying etiology, fibrosis is the main 
component of chronic liver damage that directly relates to the severity 
and prognosis of the disease. Hepatic fibrosis and its secondary result, 
portal hypertension (PHT) are currently viewed as a dynamic process that 
can be reversible in some situation, if the underlying insult that has 
caused the fibrosis and cirrhosis has been removed. Over time, the excess 
fibrous tissue of cirrhotic liver may also regress. Therefore, an accurate 
estimation of the severity of fibrosis and PHT is essential to evaluate the 
disease state and prognosis and is the first step towards the optimization 
of the treatment and estimation of its response .51-56 
SERUM MARKERS 
 Direct markers such as serum laminin levels, serum hyaluronic 
acid and procollagen type Ⅲ propeptide were evaluated in an old small 
population studies and laminin and hyaluronic acid showed correlation 
with HVPG, however these markers has limitations in clinical application 
because of low predictive values for the presence of severe PHT.57, 58 
ELASTOGRAPHY 
 Transient elastography (TE), popularly called as Fibroscan, has 
been introduced recently for assessing the stiffness of the liver , non 
invasively which matches the accuracy of the liver biopsy in assessing 
the grade of fibrosis.59-65 It is done by the following method. 
1.  An US transducer probe, which was built on the longitudinal 
plane of a vibrator was used. Through this, a low frequency 
and mild amplitude signal is transmitted. This produces a 
wave that propagates through the hepatic tissue. 
2.  A pulse-echo acquisitions were done to quantify the spped of 
the wave propagation through the liver tissue, which is 
found to correlate with the liver stiffness. 
  
Figure  30: Showing the mechanism of Fibroscan and reading of a 
grade 4 fibrotic liver with liver stiffness score of 49.6 kPa 
 The area of the hepatic parenchyma which can be evaluated by 
Fibroscan is approximately hundred times larger than that estimated by 
biopsy. Hence there is a low potential for sampling error. As the liver 
gets fibrosed during the course of the chronic liver disease / cirrhosis, the 
stiffness level of the organ increases proportionately and hence transient 
elastography has been used to evaluate the presence of fibrosis and 
cirrhosis, and was found to be an effective analysing tool in this setting.  
Stiffness of the liver is measured as kilopascals (kPa) or centimeters per 
second (cm/s). However to get a single cut-off value to differentiate 
chronic liver disease from cirrhosis is difficult, as the liver stiffness varies 
with the etiology of the chronic liver disease and its also varies between 
different geographical location. However, a cut-off value of 12.6 kPa and 
over has been estimated to differentiate cirrhosis, in a recent prospective 
study done in patients with chronic liver disease.66 Stiffness of the liver 
has been shown to correlate best with the viral etiologies, especially 
Hepatitis C and correlates well with the severity of the fibrosis.67 
 The effectiveness of transient elastography in the non-invasive 
estimation of portal hypertension and CSPH have also been analysed. In a 
recent study done in patients with recurrent hepatitis C infection post 
liver transplantation, liver stiffness measured, was found to have 
excellent correlation with the degree of fibrosis and with HVPG. They 
found that, a liver stiffness value of 8.73 kPa had a sensitivity and 
specificity of 91% and 80% for the diagnosis of any grade of portal 
hypertension (HVPG 6 mmHg). Along with this, in cirrhotic patients, 
liver stiffness has been found to correlate well with the presence of high 
grade oesophageal varices. In the prospective study by Kazemi et al, they 
found a liver stiffness value above 19.5 kPa predicted the presence of 
high grade oesophageal varices.68 In another recent study, though 
published as an abstract, a significant correlation has been shown 
between HVPG and liver stiffness in a population of uncomplicated 
alcoholic and HCV-related cirrhotic patients; they found a cut-off value 
of 17.2 kPa had a sensitivity of 92% for the clinically significant portal 
hypertension.68, 69 In addition two further studies showed the cut-off 
values of respectively, 23.4 and 13.5 kPa had a good accuracy to predict 
the presence of CSPH (HVPG > 12mmHg) in patients with chronic liver 
disease.70, 71 However, it has been stressed  in the study by Vizzutti and 
colleagues, that at the threshold value of 13.7 kPa there was no good 
correlation between liver stiffness and CSPH, probably because once 
portal hypertension progresses above a the threshold HVPG value of 10– 
13mmHg, porto-systemic collaterals forms and thereby, the hepatic 
fibrosis is not the only mechanisms maintaining portal hypertension, as 
porto-systemic collateral flow increases and significantly contributes.72 In 
a recent study done, transient elastography was evaluated for the 
diagnosis of CSPH in the setting of resectable hepatocellular carcinoma 
patients.73-75 Their result showed that TE is not an accurate method to 
rule-out or confirm CSPH in this population, and they recommended TE 
not is used as a non-invasive surrogate marker for indicating or 
contraindicating surgery. To conclude from these observations, though it 
has been estimated that higher values of liver stiffness at TE showed 
strong predictive value for cirrhosis and the presence of CSPH, the 
technique is not effective enough to analyse the severity of portal 
hypertension. 
 
 
MR ELASTOGRAPHY (MRE) 
 MRE is a recent technique with novel MRI technology to evaluate 
liver stiffness. The parameters are obtained by synchronizing motion-
sensitive imaging series with the application of acoustic signals in the 
tissue media. It has been evaluated in humans, and the initial report has 
shown satisfactory results supporting its practicability in estimating the 
stage of hepatic fibrosis in patients with chronic liver disease.76 MR 
elastography can be repeated multiple times and changes correlate well 
with the progression of tissue fibrosis. MR elastography has also been 
evaluated for estimation of the spleen stiffness, which was highly 
correlated with hepatic stiffness.77  And spleen stiffness was found to 
have a close correlation with portal pressure. Even though MRE has some 
technical superiority over Fibroscan (no need an acoustic window, a 
freely-oriented view field, no sensitivity to body habitus) it is not cost 
effective, as it is more expensive and time consuming. Also it will only 
used when the patient is already subjecting to undergo MRI for some 
other reasons. 
 
 Figure 31: MR Elastography-An elastrogram of a healthy 
patient showing a post processed value of 1.98 kPa corresponding to 
normal tissue stiffness. An elastogram of the liver of a patient with 
Grade 3 fibrosis, with a shear stiffness value of 6.95 kPa. 
 
ACOUSTIC RADIATION FORCE IMPULSE IMAGING (ARFI) 
 ARFI is a recent novel technology that gives information about the  
elasticity of the tissues in real-time. Short duration (∼ 263 μs) acoustic 
signals are produced and cause the propagation of shear waves which 
cause minimum displacements within the local tissue. The shear wave 
velocity (metre per second) is analysed in a little area of the hepatic 
parenchyma (11 mm long × 5 mm wide). It has the advantage of being 
associated with a conventional US system, thereby allowing control of 
the sampling location within the hepatic parenchyma. Recent meta 
analysis showed that ARFI can be same accuracy as TE by Fibroscan for 
evaluating the severity of liver fibrosis and detection of cirrhosis in 
patients with chronic liver diseases.78 
HEPATIC VENOUS PRESSURE GRADIENT 
 HVPG measurement through the internal jugular vein route is the 
gold standard method to evaluate the presence and grade the severity of 
portal hypertension. However the fact that it is invasive and more so that 
it is not available in all centres across the country to assess and to 
evalaute the progression of the liver diseases has been the main limiting 
factor for its use as a common practical tool. Also patients are unwilling 
to subject themselves to an invasive investigation when other non 
invasive methods are available and they can get a fairly a rough estimate 
of the severity of the liver disease. This is even more important when the 
procedure needs to be repeated to monitor treatment response. These 
problems have created more interest to non-invasively estimate when 
CSPH is present, so allowing defining the patient population who are 
prone for developing portal hypertension-related complications. 
 
 
  
 
 
 
 
 
 
 
 
 
Figure 32:  Schematic diagram showing the procedure of measuring 
HVPG and their readings. 
 
RECENT ADVANCES - MRI IN ASSESSMENT OF CIRRHOSIS 
AND PORTAL HYPERTENSION 
 Recently, various MR imaging based techniques have been 
evaluated in assessment of hepatic fibrosis, including conventional 
contrast MR imaging, including double contrast-enhanced MR imaging, 
MR perfusion imaging, diffusion-weighted imaging  and MR 
spectroscopy.79-81 
 Figure 33: Fat suppressed axial T2W FSE image showing diffuse 
reticular network throughout the liver, indicating fibrosis 
DIFFUSION-WEIGHTED IMAGING 
 Diffusion is random movement of water protons and the process by 
which water protons moves in space is called BROWNIAN MOTION.82 
 
Figure 34: Showing the mechanism of diffusion weighted imaging. 
 Diffusion-weighted imaging helps in assessing the diffusion of 
protons within local tissue by application of various motion sensitizing 
gradients that cause the diffusing protons to lose signal. This signal loss 
is quantified and it is affected by two variables. 
1. Influenced by the strength of the diffusion weighting b value 
of the sequence is the diffusion sensitivity parameter and  
2.  The ability of the protons to diffuse through the local tissue. 
 
 
Figure 35: The basis of current diffusion-weighted imaging-  
The Stejskal-Tanner technique. 
 
 Until recently, higher quality liver DWI was not attainable because 
of the relatively short T2 of the liver. Also the unavoidable physiologic 
motion in the abdomen, the susceptibility effects, and other factors. 
However, the recent implements of high performance gradients and 
parallel imaging, the image acquisition has improved tremendous, 
increasing the  quality of diffusion-weighted imaging of the liver.  
 In view of its efficacy in evaluating the changes in the brain 
density and the different pathologies, initially DWI was applied as an 
experimental study in the assessment of hepatic fibrosis. A central 
background behind use of diffusion weighted imaging for this purpose is 
that water diffusion is restricted by fibrosis. However, till date hepatic 
DWI was not to achieve a good image quality has not achieved sufficient 
image quality to permit direct visualization of fibrosis, and interpretation 
relies on estimation of the ADC.83 
APPARENT DIFFUSION COEFFICIENT 
 ADC is a measure of diffusion. It is calculated from b-value zero 
and higher b-values. Diffusion restricted areas appears bright on diffusion 
weighted images and dark areas on ADC maps. The ADC is calculated 
by analysing the signal lost between the two images obtained with 
various b values. Atleast two b values are needed to see the difference. 
However most of the units have used three or more b values. In the 
calculation leverage was given for the decay due to Monoexponentiality. 
The directional vector of the motion-sensitizing gradient has no influence 
on the images, and anisotropy was not seen yet. 84 
 Figure 36: Illustration of the free and restricted diffusion of  
water in different tissues. 
 
 Initial DWI studies on the liver used fat-suppressed DWI sequence 
which revealed decreased ADC in cases of chronic liver disease 
compared to other causes. This paid the way for development of various 
technique and protocol for staging the chronic liver disease by finding the 
different stages of fibrosis. However, initial studies with few number of 
patients and hardware and sequencing issues showed inconsistent results 
for staging liver fibrosis with diffusion-weighted imaging. 
 Figure 37: A patient with hepatitis C and related stage III fibrosis. 
DWI obtained with b value of 0 (a) and 800 (b) s/mm2 and ADC map 
(c) are shown. Mean ADC value was 0.98 × 10−3 mm2/s. 
 There are several challenges in use of diffusion as a surrogate 
marker for fibrosis. Interpretation of the ADC is complex because there 
are several potential confounding factors, including perfusion effects, 
hepatic steatosis, hepatic iron, and liver inflammation.85, 86 In addition, 
despite technical improvements in diffusion-weighted imaging, the 
method remains sensitive to susceptibility and motion-related artifacts, 
and it is difficult to obtain images with sufficient quality for reliable 
quantitative analysis on a consistent basis. More important, the ADC 
depends on imaging parameters. Field strength, repetition time, echo 
time, and b values all affect the ADC. The manner in which a particular b 
value is achieved is also relevant. The b value indicates magnitude of 
diffusion weighting. It is expressed in sec/cm. It is determined by the 
gradient strength, gradient duration, and gradient separation. Different 
combinations of gradient strength, gradient duration, and gradient 
separation may achieve the same b value but yield dissimilar ADC 
measurements. In general, for a fixed b value, increasing the gradient 
separation reduces the ADC. Because technical factors lead to differences 
in estimated ADC, reported ADCs are variable, with considerable overlap 
between normal and abnormal ranges . Thus, there is a need to develop 
site- and technique-specific normal ranges and to standardize methods 
across imaging centers. 
 
Figure 38:  Axial echo planar diffusion-weighted images with 
different b values and ADC mapping in healthy and cirrhotic 
patients 
 
ADC LIVER AND LIVER FIBROSIS STAGE 
 Recent studies have shown that the liver ADC value of patients 
with liver fibrosis is lower than that of healthy subjects.8 It has been 
suggested that this decrease in the ADC value can be explained by the 
accumulation of glycosaminoglycane, proteoglycane and collagen fibres 
in the liver resulting in restricted water molecule diffusion with liver 
fibrosis. In a study by Koinuma et al. using 128 s/mm2 b value, a 
significant negative correlation was found between ADC and fibrosis 
score. The most limiting factor of this study is that the b value is low. 
 The hepatic mean ADC value of patients at different stages of 
chronic liver disease was found to be low compared to that of healthy 
individuals in a study by Talwalkar et al.  85 Bakan et al. found that ADC 
values decreased as the fibrosis stage increased. However, there were no 
statistically significant differences in terms of the mean liver ADC values 
between stages 0 and 1 and stages1 and 2. 87Though DWI was helpful in 
differentiation of later fibrosis stages and intermediate fibrosis stages, 
DWI was not reliable in discriminating between early fibrosis stages. 
This situation can be explained by the localisation and small amount of 
fibrosis in F1 and F2 groups. In chronic hepatitis, fibrosis starts in the 
portal areas so in F1 and F2.  In F3, the bridging fibrosis which connects 
the portal tracts are the parenchymal distortion first detected. 
 
 
 Figure  39: ( a–c) MRI upper abdominal ADC mapping images of 
cirrhotic patient with stage F3 fibrosis. (d–f) DWI images at same 
sections. 
 
 
 
 
 
 
 
  
MATERIALS AND METHODS 
Study design - Prospective Observational 
Sampling  - Simple random sampling 
Place of Study 
 Rajiv Gandhi Government General Hospital, Madras Medical 
College. 
Duration of Study 
 June  2014 to September 2014. 
Inclusion Criteria 
Case 
 Patients admitted with cirrhosis of various etiology were 
evaluated 
 Age > 20 yrs was evaluated. 
Control 
 Patients with normal liver function test. 
 No history of chronic or acute liver disease. 
Exclusion criteria 
 Patients taking treatment for portal hypertension 
 Absolute contraindication to MRI 
 Patient refusing MRI 
Study Methodology 
 This prospective study was performed after obtaining clearance 
from our institutional ethical committee. 
 As this study is the first of its kind done on portal hypertension 
patients, we initially planned to find out any difference and the 
characteristics of the MRI spleen findings of chronic liver disease / 
cirrhosis patients compared to a control group with no liver disorders.  
 Patients admitted with clinical and examination findings of chronic 
liver disease/ cirrhosis were evaluated with detailed history and clinical 
examination involving the symptoms of cirrhosis like gastrointestinal 
bleeding, index bleed, ascites, therapeutic paracentesis and hepatic 
encephalopathy along with the etiology of cirrhosis. Their investigations 
were reviewed to confirm the etiology, evidence of hypersplenism 
(hemoglobin,white blood cell count and platelet count), Child Pugh’s 
status and Model for End stage Liver Disease  (MELD) score ( Serum 
bilirubin in mgms%, serum albumin in gms%, serum creatinine in 
mgms%, International normalized ratio (INR)) to assess the severity of 
chronic liver disease. Upper gastrointestinal endoscopy findings of the 
patient done at the initial visit  or the highest grade of the esophageal 
varices were noted along with USG abdomen findings of the size and 
echotexture of the liver along with spleen size, portal vein diameter and 
grade of ascites (no/moderate/ severe). Patients undergoing treatment for 
portal hypertension were not evaluated as this might be an confounding 
variable on the ADC value. Finally the patients were subjected for MRI 
examination after informed consent. The protocol will be as follows: 
 Using 1.5 tesla, diffusion weighted imaging/opposed / inphase 
imaging  was performed in cirrhotic and control patients. 
1. b value of 0, 300, 500 are used. Time to repeat (TR) of 100 
millisecond(ms) and Time to echo (TE) of 2.1ms for opposed 
phase and 4.2 ms for inphase were used. Slice thickness of 5mm, 
matrix size of 256*256 are used. ).  
2. ADC value of the spleen along with liver was calculated   
3.  In phase and opposed phase of the liver and spleen was also 
calculated 
 For control, patients who undergo MRI abdomen investigation for 
other reasons with normal liver function test were included and the above 
mentioned values were calculated. 
  
DEFINITIONS 
1. ”A diagnosis of Chronic liver disease/cirrhosis was made based on 
the combination of clinical presentation, doppler findings, and liver 
function test. 
2. Esophageal varices were graded according to Conn’s 
classification.88 
• Grade 1 – Small varices, only detectable on performing 
Valsalva maneuver 
• Grade 2 – Small varices (1-3mm) visible without a valsalva 
maneuver 
• Grade 3 – Varices of moderate size ( 4-6mm) 
• Grade 4 – Large varices ( > 6mm)” 
3. Clinically significant portal hypertension 
“Clinically significant portal hypertension was defined as the 
presence of either oesophageal or gastric variceal bleed, portal 
hypertensive gastropathy, or thrombocytopaenia (platelet count 
<100000/cu.mm) associated with splenomegaly.” 
4.  Child Pugh class of Chronic liver disease 
  
“Child-Pugh Criteria for Hepatic Functional Reserve 
Clinical and laboratory 
measurement 
1 2 3 
Encephalopathy (grade) None 1 or 2 3 or 4 
Ascites None Mild Moderate 
Bilirubin (mg/dL) 1-2 2.1-3 ≥3.1 
Albumin (g/dL) ≥3.5 2.8-3.4 ≤2.7 
Prothrombin time (increase, s) 1-4 4.1-6 ≥6.1 
 
Grade A, 5-6; grade B, 7-9; grade C, 10-15 
5. MELD = 3.8[Ln serum bilirubin (mg/dL)] + 11.2[Ln INR] + 9.6 
[Ln serum creatinine  (mg/dL)] + 6.4   where  Ln is the natural 
logarithm” 
6. Hypersplenism 89 
 “It was defined as the presence of splenomegaly with a defect in 
any one of the peripheral cell lines (anaemia - hemoglobin less 
than 8 gm/dL with normocytic and normochromic appearance in 
peripheral smear; a leukocyte count of <3500/mm3 and a platelet 
count of <150000/mm3).  “ 
7. Symptomatic hypersplenism. 90 
“Symptomatic hypersplenism was defined as requirement of 
repeated blood transfusions or symptoms of anemia with no 
obvious cause, recurrent infections, spontaneous bleeding episodes 
(epistaxis, gum bleed, menorrhagia etc).” 
8. Degree of splenomegaly was classified using Hackett’s 
 classification. “Class Findings on palpation 
0.  Spleen not palpable even on deep inspiration 
1.  Spleen palpable below costal margin, usually on deep 
inspiration. 
2.  Spleen palpable, but not beyond a horizontal line half way 
between the costal margin and umbilicus, measured in a line 
dropped vertically from the left nipple. 
3.  Spleen palpable more than half way to umbilicus, but not 
below a line horizontally running through it. 
4.  Palpable below umbilicus but not below a horizontal line 
half way between umbilicus and pubic symphysis. 
5.  Extending lower than class 4.” 
 Hackett’s classes 1 and 2 were considered as mild splenomegaly, 
class 3 as  moderate splenomegaly, and classes 4 and 5 as massive 
splenomegaly 
9.  Ascites 
Grade 1: mild, only visible on ultrasound and CT 
Grade 2: detectable with flank bulging and shifting dullness 
Grade 3: directly visible, confirmed with the fluid wave/thrill test 
 
10.  Hepatic encephalopathy - The severity of hepatic encephalopathy 
is graded with the “West Haven Criteria91 
Grade 1 - Trivial lack of awareness; euphoria or anxiety; shortened 
attention span; impaired performance of addition or 
subtraction 
Grade 2 - Lethargy or apathy; minimal disorientation for time or 
place; subtle personality change; inappropriate 
behaviour 
Grade 3- Somnolence to semistupor, but responsive to verbal 
stimuli; confusion; gross disorientation 
Grade 4- Coma (unresponsive to verbal or noxious stimuli)” 
 
 
 
 
 
 
 
 
 
STATISTICAL ANALYSIS 
 Statistical analysis was done using Graphpad instat ver.3.0.  
 Student’s t tests  was used in the comparison of numerical 
variables (mean ages,liver size, spleen size, PV diameter, laboratory 
values, liver and spleen ADC values) between the patient group and the 
control group. Differences were considered to be statistically significant 
at p < 0·05. 
 Mann U Whitney test was used in comparison of different stages of 
liver fibrosis, Grades of varices, Child Pugh class and MELD grade to the 
ADC value of the patients.  
 Chi square test was used in comparison of the ADC value of the 
patient to different portal hypertension surrogate markers  and CSPH. 
Mann U Whitney test was performed in the comparison of mean 
ADC values of the patients at different stages ( non parametric variables) 
and the control group. Differences were considered to be statistically 
significant at p < 0·05 
 
 
 
 
 
 RESULTS 
MRI SPLEEN - CONTROL VS CHRONIC LIVER 
DISEASE PATIENTS 
 We initially compared 15 patients from each group (case and 
control) to analyse the difference in MRI findings of the spleen in DWI. 
The 15 control patients were selected ruling out any liver pathology in 
them by clinical, biochemical and imaging findings. 
 We analysed the demographics of both group and found both group 
to be matched with no significant  difference between the age and sex of 
the patients. Table.1 
 
Table 1:  Demographics of the matched case and control group 
Variable Case (15) Control (15) P value 
Age (yrs) 43 (32-60) 42 (22-59) 0.9 
M:F 12:3 10:5 0.6 
 
 
 
 
 CHARACTERISTICS OF THE CHRONIC LIVER DISEASE 
PATIENTS 
 We analysed 15 chronic liver disease patients, of which most of 
them are Child Pugh class A patients (7), with alcohol as the predominant 
etiology. 10 out of the 15 were GI bleeders and eight of them had 
hypersplenism (Table.2) 
Table . 2 – Characteristics of the case group. 
VARIABLE 
 
Child’s Pugh status (A:B:C) 7:5:3 
Etiology 
Alcohol- 7 
Viral = 5 
NASH- 2 
Cryptogenic- 1 
History of GI bleed Bleeder- 10/15 
History of  hypersplenism 8/ 15 
 
NASH – Non alcoholic steatohepatitis, GI- Gastrointestinal 
 
 COMPARISION OF THE CHARACTERISTICS OF CASE AND 
CONTROL GROUP 
 When the clinical and biochemical parameters were compared 
between the two groups, there were significant differences in parameters 
of chronic liver disease like hypersplenic features, liver span, spleen span 
and serum bilirubin, serum creatinine and INR (Table.3) 
Table.3- Comparision of the clinical and biochemical parameters 
VARIABLES Case (15) Control (15) p value 
Hemoglobin (gm/dL) 8.4 ±2 11.9 ± 1.3 0.04 
WBC (cu.mm) 5120 ±1392 6710 ± 1151 0.12 
Platelet count (cu.mm) 
102000 ± 
25000 
316000 ± 
11200 
0.016 
Liver size (cm) 10.4± 2.4 13.2 ± 0.5 0.01 
Spleen size (cm) 15.6 ± 2.4 9 ± 0.7 0.01 
Portal vein 
diameter(mm) 
13.7 ± 1.1 9.3 ± 0.4 0.04 
Serum Bilirubin 
(mg/dL) 
5.6 ± 2.3 0.74 ± 0.7 0.001 
INR 1.7 ± 0.5 1.04 ± 0.1 0.02 
Serum creatinine 1.2 ± 0.5 0.79 ± 0.4 0.04 
INR- International normalized ratio, WBC – white blood count 
(cu.mm) 
ADC CHARACTERISTICS OF THE SPLEEN AND LIVER  
 When the ADC value of the spleen and liver was analysed between 
the case and control group, we found significant difference in the ADC 
values. ADC value of the spleen increased (117.4 ± 28.4  Vs 80.7 ± 9.1, 
p=0.04) significantly in chronic liver disease patients whereas ADC value 
of the liver significantly decreased (107.2 ± 41.8 Vs 338.9 ± 31.1, 
p=0.001)   in  the case group. We also analysed the Inphase and Oppose 
phase of the liver and spleen and found significant difference between 
both groups.  
Table : 4  ADC spleen and Liver (mm2/s )– Case Vs Control 
VARIABLES Case (15) Control (15) p value 
ADC 
LIVER(mm2/s) 
107.2 ± 41.8 338.9 ± 31.1 0.001 
ADC 
SPLEEN(mm2/s) 
117.4 ± 28.4 80.7 ± 9.1 0.04 
Inphase Liver 131.1 ±54.3 206 ± 11.3 0.001 
Inphase spleen 78.7 ± 21.1 148.3 ± 13.9 0.02 
Oppose Liver 124.2 ± 46.7 205.8 ± 28.9 0.01 
Oppose spleen 70.1 ± 21.5 157.8 ± 9.3 0.03 
 ADC SPLEEN AND CHRONIC LIVER DISEASE 
 We analysed the 51 chronic liver disease patients managed in our 
hospital from July 2014 - September 2014. Their clinical and biochemical 
parameters were analysed with their imaging findings and after informed 
consent underwent DWI of the abdomen.(Figure.1 ) 
Figure 1:  Etiology of the 51 chronic liver disease patients 
 
DEMOGRAPHICS AND CLINICAL CHARACTERISTICS OF 
THE PATIENTS 
 Out of the 51 chronic liver disease patients, most of them belong to 
Child Pugh’s class A (29/51) status with 9 patients of Child’s class C 
status. Their mean age was 49.6 ± 12.3 with 38 of them males. (Figure.2) 
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Figure 2:  Child Pugh class of the 51 patients
 
Figure 3:  X Y scatter diagram of the age distribution in the  
CLD patients 
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Figure 4:  Sex distribution of the CLD patients 
 
 
 
CLINICAL and BIOCHEMICAL CHARACTERISTICS OF THE 
CLD PATIENTS 
 All 51 patients were reviewed of their medical history and their 
biochemical parameters were analysed. Since 29 patients belong to 
Child’s A status, there were no ascites in any of them. Most of them had 
hypersplenism with their mean hemoglobin of 8.42 ± 2.1gms%, WBC 
count of 5820 ± 1720/ cu.mm and platelet count of 100313 ± 25189 / 
cu.mm. Out of the 51 patients, 32 patients were bleeders with 4 patients 
having grade 4 varices. Their median MELD score 11.  
 
38 
13 Male 
Female 
Table  5: Clinical and biochemical characteristics of the CLD 
patients 
VARIABLES Value 
Esophageal varices 
Grade 1-4 
16/15/15/4 
Hemoglobin(gms%) 8.42 ± 2.1 
WBC(cu.mm) 5820 ± 1720 
Platelet count(cu.mm) 100313 ± 25189 
Liver span(cms) 9.79 ± 2.37 
Spleen size(cms) 15.4 ± 2.32 
Portal vein diameter(cms) 1.35 ± 0.1 
Splenomegaly 
No: Mild: Moderate: Severe 
9: 22:15:5 
Ascites 
No:Mild: Moderate: Severe 
29:4:13:5 
Se.Bilirubin(mg%) 3.5 ± 1.6 
Se.Creatinine (mg%) 1.1 ± 1.3 
INR 1.35 ± 0.9 
Se.Albumin(gm/dL) 2.8 ± 1.2 
 
PORTAL HYPERTENSION FEATURES OF THE CLD PATIENTS 
 We also analysed the portal hypertensive surrogate features of 
these 51 patients and found that most of them are hypersplenic (42/51= 
82%) with 37% of them are symptomatic hypersplenism. Only 10 
patients have suffered mild grade of encephalopathy. 
Table 6:  Portal hypertensive features of the CLD patients 
VARIABLES Yes No 
History of GI bleed 32 19 
Hypersplenism 42 9 
Symptomatic 
Hypersplenism 
19 32 
Hepatic encephalopathy 8 43 
Controlled ascites 38 13 
 
 
 
 
 
 
ADC OF THE SPLEEN WITH SEVERITY OF PORTAL 
HYPERTENSION 
 We analyzed the ADC mapping of the spleen for the 51 patients 
and compared it between the 39 patients who had clinically significant 
portal hypertension (CSPH) to the group of 12 patients who had no 
CSPH. We found the ADC value of the spleen was significantly higher 
(125.2 ± 29.6 vs 84.1 ±1.6, p value=0.05)  in the CSPH group, however 
the ADC value of the liver is non significantly lower (84.1 ±1.6 vs 125.2 
± 29.6, p value=0.09) in the CSPH group compared to the non CSPH 
group.  
 
Table 7 : Correlation between ADC value of spleen/ Liver to  
Clinically significant Portal hypertension 
VARIABLE 
ADC spleen  
(mm2/s) 
ADC Liver  
(mm2/s) 
CSPH (39) 125.2 ± 29.6 89.2 ± 20.1 
NO CSPH (12) 84.1 ±1.6 134.3 ± 11.4 
p value 0.05 0.09 
 
 
 
ADC OF THE SPLEEN AND PORTAL HYPERTENSION 
SURROGATE MARKERS 
We also analysed the ADC value of the spleen with the different 
portal hypertension surrogate markers and found that though ADC of the 
spleen were non significantly higher in the presence of increased severity 
of portal hypertension, it is the esophageal varices>grade 2 and 
symptomatic hypersplenism which had significantly higher spleen ADC 
compared to the other group. Chi square test was used for the analysis. 
Table  8:  ADC of the spleen and portal hypertension  
surrogate markers 
Portal hypertension 
surrogates 
ADC spleen  
(mm2/s) 
p Value 
Bleeder (32) 
Vs 
non bleeder (19) 
120.2 ± 29.6 
Vs 
86.1 ±1.6 
0.06 
Grade of varices 
( <=2 Vs  > 2) 
93.1 ± 9.9 
Vs 
126.6 ± 20.2 
0.04 
Symptomatic hypersplenism 
(19 Vs 32) 
123.3 ± 23.1 Vs 
90.2 ± 11.3 
0.02 
PV diameter 
(<= 13mm Vs > 13 mm) 
112.3 ± 23.1 
Vs 
123.3 ± 8.9 
0.12 
Splenomegaly 
( <= 13cm Vs > 13cm) 
109.5± 9.1 
Vs 
123.4 ± 7.8 
0.23 
ADC SPLEEN/LIVER VS SEVERITY OF CHRONIC LIVER 
DISEASE 
 As evaluated in the past studies, we also analysed the ADC value 
of the spleen and liver for different Child Pugh’s class patients and found 
that as the severity of the Child class worsens, the ADC value of the liver 
decreased (140.1 ± 13.4 vs 120.2 ± 11.3 vs 82.0 ± 9.3, p value  = 0.05 ) 
which was statistically significant. However, though the ADC of the 
spleen increased proportionately to the Child Pugh status (85.9 ± 9.4  vs 
101.4 ± 11.4  vs 121.6  ± 14.2,  p value =0.12 ) , it was not statistically 
significant.  
 
Table 9: ADC Spleen / Liver Vs Severity of chronic liver disease 
Child Pughs  
Class 
ADC LIVER 
(mm2/s) 
ADC SPLEEN 
(mm2/s) 
A 140.1 ± 13.4 85.9 ± 9.4 
B 120.2 ± 11.3 101.4 ± 11.4 
C 82.0 ± 9.3 121.6  ± 14.2 
p value 0.05 0.12 
 
 
 
 ADC SPLEEN / LIVER Vs Model for End Stage Liver Diseases 
(MELD) 
 We in addition analysed the ADC value of the spleen and liver to 
different levels of MELD score and again found that the ADC value of 
the liver significantly decreased(135.1 ± 11.4 vs 113.2 ± 16.3 vs 83.9 ± 
10.3, p value = 0.04)  according to the increasing MELD score. Here also 
the ADC of the spleen was non significantly increasing (89.9 ± 9.4 vs 
99.4 ± 11.4 vs 127.6  ± 14.2, p value = 0.09)  to the increasing MELD 
score. 
Table 10:  ADC SPLEEN/LIVER Vs  MELD 
MELD 
ADC Liver 
 (mm2/s) 
ADC Spleen  
(mm2/s) 
> 15 135.1 ± 11.4 89.9 ± 9.4 
16 - 25 113.2 ± 16.3 99.4 ± 11.4 
>25 83.9 ± 10.3 127.6  ± 14.2 
p value 0.04 0.09 
 
  
ADC SPLEEN / LIVER AND  LIVER FIBROSIS SCORE 
We could retrieve the liver biopsy findings from 10 out of the 51 
patients and found atleast one patients in every grade of fibrosis. Though 
the numbers were very small for analysis, we found that ADC of the liver 
decreased (135.1 ± 11.4 vs 113.2 ± 16.3 vs 100.3 ± 12.3 vs 83.9 ± 10.3) 
according to increasing severity of the grade of fibrosis.  
Table 11:  ADC spleen / liver and  liver fibrosis score 
Fibrosis  
score 
ADC Liver 
 (mm2/s) 
ADC Spleen 
(mm2/s) 
F1 135.1 ± 11.4 89.9 ± 9.4 
F2 113.2 ± 16.3 99.4 ± 11.4 
F3 100.3 ± 12.3 111.3 ± 10.4 
F4 83.9 ± 10.3 127.6  ± 14.2 
 
 
 
 
  
  
 
MRI CORONAL IMAGING OF A NORMAL LIVER PATIENT 
 
 
 
 
MRI  ABDOMEN (BOTH T1W AND T2W) IMAGES SHOWING 
NORMAL SPLEEN  
T1Weighted – Normal spleen hypointense than the liver 
 
T2 Weighted – Normal spleen hyperintense than the liver  
 
DWI AND ADC MAPPING OF A NORMAL STUDY 
ADC SPLEEN IS 72.5 MM2/S AND ADC LIVER IS 290.2 MM2/S 
 
 
 
 
  
 
MRI SHOWING THE FEATURES OF CIRRHOSIS 
 
 
 
 
 
  
 
MRI T2W CORONAL FSP IMAGE OF A F3 FIBROTIC LIVER 
PATIENT SHOWING GROSS SPLENOMEGALY 
 
 
 
 
 
 
 
DWI AND ADC MAPPING OF A CIRRHOTIC PATIENT  
SPLEEN ADC OF 167.8 mm2/S 
CHILD C CIRRHOSIS 
 
 
 
 
 
DWI AND ADC MAPPING OF CIRRHOTIC  PATIENT  
SPLEEN ADC OF 120.2 mm2/S 
CHILD’B CIRRHOSIS 
 
 
 
 
DWI AND ADC MAPPING OF A CIRRHOTIC PATIENT  
SPLEEN ADC OF 89.5 mm2/S 
CHILD’S A CIRRHOSIS 
 
 
 
 
 
DISCUSSION 
 DWI has been used extensively in chronic liver disease patients 
and liver ADC has been found to be a useful adjunct in predicting the 
degree of fibrosis especially in patients with viral etiology. This is due to 
the reduced perfusion in a fibrotic liver and the degree of ADC reduction 
implies the severity of fibrosis in the liver.  Similarly, cirrhosis is a state 
of hyperdynamic circulation and in view of portal hypertension, there is a 
splanchnic hyperemia. This splanchnic hyperemia is assessed in our study 
by taking spleen as the representative organ of the splanchnic circulation.  
 In our study, we found that when compared to normal patients, 
Liver ADC is significantly reduced in chronic liver disease patients. A 
growing body of literature had demonstrated that the ADC of cirrhotic 
livers is significantly lower than that of normal livers.8, 92-97 In current 
study, we confirmed this results, as we found that the mean liver ADC 
value in patients with hepatic fibrosis was significantly lower than that of 
volunteers  (1.59 ·103 mm2/s vs. 1.67 · 103 mm2/s, p =0.01). This can be 
attributed to the presence of fibrous tissue. The main component of 
fibrous tissue is collagen that associated with restricted diffusion and 
subsequent diminished ADC values. However we also found that found 
that spleen ADC is significantly increased in patients with chronic liver 
disease correlating to their splanchnic hyperemia. However this is in 
contradiction to the earlier reports except the one by Klasen who found 
that the negative correlation between spleen and liver ADC in cirrhosis 
patients.7 In chronic liver disease patients, ADC liver decreases due to 
liver fibrosis and spleen ADC increases in view of splanchnic hyperemia. 
 Normalization of ADC using a reference organ which remains 
relatively constant among patients have been used in earlier studies to aid 
in reduction of ADC calculation variability.8, 12, 95, 98 Earlier studies used 
spleen as a reliable internal standard wherever quantitative analysis using 
ratios is required as in assessing degree of signal intensity loss in adrenal 
masses in MRI. However the same spleen was used for normalization in 
studies which correlated liver fibrosis with liver ADC. Our study has 
proven the negative correlation between the ADC of liver and spleen in 
chronic liver disease and this suggest that spleen cannot be taken as a 
reference organ in chronic liver disease patients and this might have 
confounding influence on the results. 
 Though earlier studies have used spleen ADC as a reference organ 
and one recent study correlated spleen ADC with severity of chronic liver 
disease, our study is the first to correlate spleen ADC to the severity of 
portal hypertension in chronic liver disease patients.  On analysis, we 
found a significant correlation to the CSPH to the spleen ADC and also to 
the surrogate markers of portal hypertension like grade of varices, 
symptomatic hypersplenism . The mechanisms behind the significant 
positive correlation between Spleen ADC and portal hypertension have 
not been fully elucidated. In theory, elevated portal blood pressure may 
lead to vasogenic edema due to sinusoidal congestion and dilatation. As 
explained earlier there are two mechanisms for portal hypertension in 
chronic liver disease patients. One is the increased portal venous 
resistance at the sinusoidal and post sinusoidal level is usually the 
initiator of portal hypertension. However, increased portal venous inflow 
secondary to a hyperdynamic systemic circulation and splanchnic 
hyperemia is a major contributor to the maintenance of portal 
hypertension as portosystemic collaterals develop. The cause of the 
elevated cardiac output and splanchnic hyperemia is not known, but 
splanchnic hormones, such as glucagon, and decreased sensitivity of the 
splanchnic vasculature to catecholamines probably play a role. Increased 
production of nitrous oxide and prostacyclin by vascular endothelium is 
also an important factor. In our study , this splanchnic hyperemia may be 
reason for the significant association of ADC value of spleen to CSPH. 
The high ADC values are consistent with highly mobile water in areas of 
vasogenic edema. When we analysed the liver ADC to the severity of 
portal hypertension, we couldn’t find any significant correlation, impling 
the heterogeneous correlation of the severity of portal hypertension and 
severity of chronic liver disease. Similarly we found that Spleen ADC 
doesnot correlate with the severity of chronic liver disease (Child Pugh’s 
class). These two findings suggest that the spleen ADC is an indirect 
marker of splanchnic hyperemia, thereby portal hypertension and liver 
ADC is an indirect marker for the severity of liver fibrosis. This was also 
confirmed in our study as well, when we found Liver ADC decreased in 
cirrhotic patients as evident in previous studies and it correlated with 
Child Pughs class. “Even more in our study, where we could get 10 
patients liver biopsy, there was a correlation to the grade of liver fibrosis 
and liver ADC and not to spleen ADC. 
 One of the greatest challenges to widespread adoption of DWI in 
the body is the lack of standardization.92 In a prior study99, two different 
diffusion sequences were used with b values of 0, 150, 250 and 400 
mm2/s and 600 and 800 mm2/s, while in another study, b values of 0 and 
500 mm2/s were applied. As a consequence, there is a difference on 
reported ADC values of the spleen and the normal and cirrhotic liver. As 
the b values increase, ADC approaches the true diffusion coefficient, thus 
minimizing the influence of convective motion processes that are 
sensitive to diffusion-highlighting gradients, mainly perfusion in the 
randomly organized capillary network. As a general rule, lower b values 
correspond to higher mean ADCs, overestimated due to signal 
contribution from other intravoxel incoherent motions (mainly 
microvascular perfusion). On the contrary, higher b values lead to lower 
ADC values as a consequence of the gradient-enhanced signal 
degradation that eliminates fast diffusion contributions. Some 
investigators recommended the use of higher b values, possibly larger 
than 400 s/mm2, to reduce the T2 shine-through effect and make the 
ADCs determined approach the true diffusion coefficient. We took b 
value of 0, 300, 500 for finding out the true diffusion co efficient. 
 Our study is the largest series to correlate spleen ADC to the 
severity of chronic liver disease and portal hypertension. “However there 
are few limitations in our study. We didn’t use normalization of the 
spleen ADC with a reference organ to have some standardization to the 
MRI protocol in view of technical difficulties. Secondly, it was difficult 
to get patients who were not on medications for portal hypertension 
CONCLUSION 
In conclusion, our results showed that 
1. Liver and Spleen ADC values vary among patients with liver cirrhosis 
and control subjects. Liver ADC value decreases, whereas Spleen ADC 
increases with cirrhosis. 
2. ADC values in the spleen correlated well with the severity of portal 
hypertension like clinically significant portal hypertension and portal 
hypertension surrogate markers. 
3. ADC values in the spleen does not correlate significantly with the 
degree of liver disease.  
Also, the spleen might only be of limited value for normalization 
of liver ADC values to determine cirrhosis.  
4. ADC values in the liver correlate significantly with the degree of liver 
disease.  
ADC measurements may allow for noninvasive evaluation of 
portal pressure and even in assessment of treatment response. 
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ABBREVATIONS 
CTP   - Child Turcotte Pugh’s class 
ADC   - Apparent diffusion co-efficient 
US  - Ultrasound 
CT  - Computer tomography 
MRI  - Magnetic resonance imaging 
DWI  - Diffusion weighted imaging 
ARFI  - Acoustic Radiation Force Impulse Imaging 
TE  - Transient Elastography 
PH  - Portal hypertension 
TE   - Time to echo 
TR   - Time to repeat 
F1  - Fibrosis score of 1 
MRE  - MR elastography. 
HVTT - Hepatic vein transit times. 
RI  - Resistive index. 
INR  - International normalized Ratio 
HA   - Hyaluronic acid 
HVPG  - Hepatic venous wedge pressure gradient 
TIPSS - Transjugular Intrahepatic Portosystemic Shunt 
NASH  - Non alcoholic steatohepatitis 
MELD - Model for End Stage Liver Disease 
CSPH - Clinically significant portal hypertension. 
PROFORMA 
MRI DIFFUSION WEIGHTED IMAGING OF SPLEEN IN 
PATIENTS WITH CIRRHOSIS AND PORTAL 
 HYPERTENSION. 
Name:  
Age:  
Sex:  
Ip/ op number:  
Address:  
Contact number:  
 
History 
1. Variceal bleed – y/n 
2. Number of episodes-  
3. Index bleed- 
4. Abdominal distention with free fluid- 
5. History of hepatic encephalopathy- 
6. History of breathlessness. 
7. Symptoms of hypersplenism. 
8. History of etiology - alcoholism / viral hepatitis (b and c) / 
diabetic/ hypertension/ others 
Examination findings. 
Signs of liver cell disease- y/n 
Mention the positive findings-  
1. 
2. 
3. 
4. 
Investigation 
Investigations Values 
1. Hemoglobin  
2. White blood cell count  
3. Platelet count  
4. Serum bilirubin  
5. Serum albumin  
6. Serum creatinine  
7. INR  
 
8. Upper GI scopy findings – 
1. Esophageal varices-grade-        columns- 
2.  Esophageal varices – grade-     columns- 
 
9. USG abdomen –  Liver-  size   echotexture 
Spleen size 
Portal vein diameter   flow  
Ascites 
10. DWI MRI 
Parameters  
ADC liver   
ADC spleen   
Inphase liver   
Inphase spleen   
Opposed phase liver   
Opposed phase  spleen   
PATIENT INFORMATION SHEET 
INFORMED CONSENT 
 We are conducting a study “MRI Diffusion weighted 
imaging(DWI) of spleen in patients with cirrhosis and portal 
hypertension” among those who attend Government General Hospital, 
Chennai.  
 Cirrhosis is the advanced stage of liver disease and it is manifested 
in the form of blood vomiting, fluid in the abdomen, altered sensorium, 
splenomegaly, etc. Portal hypertension (increased blood pressure in the 
bllod supply to the liver) is one of the   manifestation of cirrhosis.  
 The purpose of this study is to observe the changes in spleen by 
DWI MRI in these patients and to find any correction with the severity of 
portal hypertension.  
 By taking part in the study, you have to undergo MRI examination 
which is the same as any routine MRI examination with no extra drugs. 
 The privacy of the patients in the research will be maintained 
throughout the study. In the event of any publication or presentation 
resulting from the research, no personally identifiable information will be 
shared. 
 Taking part in this study is voluntary. You are free to decide 
whether to participate in this study or to withdraw at any time; your 
decision will not   result in any loss of benefit to which you are otherwise 
entitled. 
The results of the special study may be intimated to you at the end 
of the study period or during the study if anything is found abnormal 
which may aid in the management or treatment.  
 
Signature of the Investigator           Signature of the Participant 
 
Bµõ´a] uPÁÀ uõÒ 
 
~sPv¶°¯À ©¸zxÁ £Sv 
 
 ö\ßøÚ Aµ_ ö£õx©¸zxÁ©øÚUS Á¸® PÀ½µÀ 
£õv¨£øh¢u ÷{õ¯õÎPÎß ©spµø» G®.Bº.á (MRI) »® 
Bµõ´a] ö\´uÀ. 
PÀ½µÀ  £õv¨£øhÁuõÀ ÷£õºhÀ GßÝ® ]øµ°À  E¯º 
Cµzu AÊzu® HØ£kQßÓx. Ax Á°ØÔÀ }ºPmkuÀ, Cµzu Áõ¢v, 
©spµÀ ÃUP®, _¯|øÚÄ  u¨¤¨÷£õuÀ  ÷£õßÓøÁPÍõP 
öÁÎ¨£kQßÓx.  CvÀ ©spµ¼À HØ£kQßÓ  ©õØÓzøu 
G®.Bº.á Bµõ´a]°ß »® PshÔ¢x Bµõ´Q÷Óõ®. 
CuÚõÀ u[PÍx ÷{õ°ß B´ÁÔUøP÷¯õ AÀ»x ]Qaø\÷¯õ 
£õv¨¦US HØ£hõx Gß£øu²® öu¶ÂzxU öPõÒQ÷Óõ®. 
C¢u Bµõ´a]°À £[÷PØ£x u[PÐøh¯ Â¸¨£zvß  ÷£¶À 
uõß C¸UQÓx. ÷©¾® }[PÒ G¢÷{µ¬® C¢u Bµõ´a]¼¸¢x 
¤ßÁõ[P»õ® Gß£øu²® öu¶ÂzxU öPõÒQ÷Óõ®. 
C¢u  ]Ó¨¦¨ £¶÷\õuøÚPÎß ¬iÄPøÍ Bµõ´a]°ß÷£õx 
AÀ»x  Bµõ´a]°ß ¬iÂß ÷£õx u[PÐUS AÔÂ¨÷£õ® 
Gß£øu²® öu¶ÂzxUöPõÒQ÷Óõ®. 
 
 
Bµõ´a]¯õÍº øPö¯õ¨£®     £[÷PØ£õÍº øPö¯õ¨£® 
 
÷uv: 
 
Bµõ´a] J¨¦uÀ Piu® 
 
Bµõ´a] uø»¨¦ 
 PÀ½µÀ £õv¨£øhÁuõÀ ÷£õºhÀ ]øµ°À HØ£kQßÓ 
E¯ºCµzu AÊzuzvÚõÀ ©spµ¼À HØ£kQßÓ ©õØÓzvøÚ 
G®.Bº.á Bµõ´a] »® PshÔuÀ. 
 
ö£¯º     EÒ÷{õ¯õÎß Gs. 
Á¯x     Bµõ´a] ÷\ºUøP Gs. 
£õÀ 
 C¢u Bµ¯ºa]°ß ÂÁµ[PÐ® Auß ÷{õUP[PÐ®. 
¬Êø©¯õP GÚUS öuÎÁõP ÂÍUP¨£mhx. 
 GÚUS ÂÍUP¨£mh Âå¯[PøÍ {õß ¦¶¢x öPõsk {õß 
GÚx \®©uzøu öu¶ÂUQß÷Óß. 
 C¢u Bµõ´a]°À ¤Ó¶ß  |º¨£¢uªßÔ Gß ö\õ¢u 
Â¸¨£zvß ÷£¶À uõß £[S ö£ÖQ÷Óß. ©ØÖ® {õß C¢u 
Bµõ´a]°¼¸¢x G¢÷{µ¬® ¤ßÁõ[Põ»® Gß£øu²® AuÚõÀ 
G¢u £õv¨¦® HØ£hõx Gß£øu²® {õß ¦¶¢x öPõs÷hß. 
 {õß  “PÀ½µÀ £õv¨£õÀ ©spµ¼À HØ£kQßÓ ©õØÓzøu 
G®.Bº.á °ß »® PshÔuÀ” £ØÔ C¢u Bµõ´a]PõÚ ÂÁµ[PøÍU 
öPõsh uPÁÀPøÍ¨ ö£ØÖU öPõs÷hß.  
 {õß GßÝøh¯ _¯ |øÚÄhß ©ØÖ® ¬Ê _u¢vµzxhß 
C¢u ©¸zxÁ Bµõ´a]°À GßøÚ ÷\ºzxU öPõÒÍ  
\®©vUQßÓ÷ß. 
 
øPö¯õ¨£® 
Name
Child 
Pugh 
status Sex Age
Variceal 
bleed
Hep 
encep
Hypersp
lenism Etiology Hb WBC Platelet Bilirubin
Albumi
n
creatin
ine INR
Eso 
varices 
grade 
Liver 
echo
Liver 
size
Dopp 
spleen
Dopp  
PV Ascites
ADC 
liver
ADC 
spleen
Inphas
e liver
Inphas
e 
Spleen
Oppos
ed liver
Oppos
ed 
spleen
Kulandivelu A M 43 no no no Alcoholic 6.8 7600 135000 3.4 2.7 1.1 1.4 2 Coarse 10 13.5 13.2 no 110 98 89.8 62.8 110 68.6
Palani A M 42 no no no HBV 7.8 5700 185000 2.1 3.2 0.8 1.3 1 Coarse 9 13 14.9 no 113 100.2 88.2 81.3 107.4 93.6
Sugirtham A F 52 yes no no Alcoholic 11.9 4200 87000 2.4 3 0.7 1.2 1 Coarse 12.5 19.5 12 no 167 89 200 98 149 92
Deivaraj A M 38 yes no yes Alcoholic 6 8600 56000 2.3 3.8 1.1 1.4 2 Coarse 9 15.5 13 no 142 90 82.5 42 84.7 44.4
Anandaraj A M 43 no no no Alcoholic 6.8 7600 175000 2.1 3 0.6 1.1 2 Coarse 10 13.5 13.2 no 110 98 89.8 62.8 110 68.6
Periaswamy A M 42 no no yes HCV 7.8 5700 45000 2.1 3.2 0.9 1.3 2 Coarse 11 13 14.9 no 123 100.2 88.2 81.3 107.4 93.6
Latha A F 52 yes no yes Crytogenic 11.9 4200 87000 1.6 3 1.1 1.2 1 Coarse 9 19.5 12 no 167 101 200 98 149 92
Saravanan A M 43 no no no Alcoholic 6.8 7600 135000 1.6 3 0.8 1.2 2 Coarse 11 13.5 13.2 no 110 98 89.8 62.8 110 68.6
Pechimuthu A M 42 no no yes HCV 7.8 5700 78000 2.1 3.2 1.1 1.2 2 Coarse 11 13 14.9 no 112 100.2 88.2 81.3 107.4 93.6
Lakshmi A F 52 yes no no Crytogenic 11.9 4200 87000 1.5 3 0.8 1.3 1 Coarse 9 19.5 12 no 156 103 200 98 149 92
Durai A M 38 yes no no Alcoholic 6 8600 180000 1.4 3.8 1.1 1.2 1 Coarse 10 15.5 13 no 142 123 82.5 42 84.7 44.4
Sridhar A M 43 no no no Alcoholicic 6.8 7600 135000 1.2 3 0.9 1.1 2 Coarse 9 13.5 13.2 no 110 98 89.8 62.8 110 68.6
Naluswamy A M 42 no no yes HBV 7.8 5700 45000 2.3 3.7 1.1 1.1 1 Coarse 11 13 14.9 no 98 100.2 88.2 81.3 107.4 93.6
Savathri A F 52 yes no no Biliary 11.9 4200 87000 1.5 3 0.8 1.1 1 Coarse 9 19.5 12 no 167 128 200 98 149 92
Periakarupan A M 43 no no no Crytogenic 6.8 7600 150000 1.5 3 0.9 1 2 Coarse 9 13.5 13.2 no 110 98 89.8 62.8 110 68.6
Pari A M 42 no yes yes HCV 7.8 5700 67000 1.4 3.2 0.9 1.3 2 Coarse 11 13 14.9 no 98 100.2 88.2 81.3 107.4 93.6
Mariammal A F 52 yes no no NASH 11.9 4200 87000 1.5 3 0.9 1.3 1 Coarse 12.5 19.5 12 no 145 112 200 98 149 92
Senthil A M 38 yes yes yes NASH 6 8600 56000 1.4 3.8 0.6 1.2 2 Coarse 9 15.5 13 no 142 132 82.5 42 84.7 44.4
Nagendran A M 43 no no no Cryptogenic 6.8 7600 135000 1.6 3 0.7 1.3 2 Coarse 13 13.5 13.2 no 110 98 89.8 62.8 110 68.6
Anandaraj A M 42 no no yes HBV 7.8 5700 125000 1.7 3.2 0.6 1.4 1 Coarse 9 13 14.9 no 102 100.2 88.2 81.3 107.4 93.6
Rajendran A M 52 yes no no Alcoholic 11.9 4200 87000 2.1 3 1.1 1.1 1 Coarse 9 19.5 12 no 182.7 112 200 98 149 92
Kumar A M 43 no no no Crytogenic 6.8 7600 135000 2.2 3 1.1 1.3 2 Coarse 13 13.5 13.2 no 110 98 89.8 62.8 110 68.6
Nandhakumar A M 42 no no yes HCV 7.8 5700 125000 3.4 3.2 1.3 1.4 2 Coarse 12 13 14.9 no 108 100 88.2 81.3 107.4 93.6
Muniammal A F 52 yes no no Alcoholic 11.9 4200 87000 1.8 3 1.4 1 1 Coarse 9 19.5 12 no 188 119 200 98 149 92
Sethu A M 38 yes no yes NASH 6 8600 107000 1.4 3.8 1.1 1.2 1 Coarse 12 15.5 13 no 142 124 82.5 42 84.7 44.4
Kaliappan A M 43 no no no Crytogenic 6.8 7600 135000 1.9 3 1.2 1.5 1 Coarse 13 13.5 13.2 no 110 98 89.8 62.8 110 68.6
Pechiswamy A M 42 no no yes Biliary 7.8 5700 125000 2.1 3.2 1.3 1.2 1 Coarse 16.5 13 14.9 no 112 100.2 88.2 81.3 107.4 93.6
Aruna A F 52 yes no no Alcoholic 11.9 4200 87000 1.9 2.6 1.6 1.2 1 Coarse 9 19.5 12 no 190 108 200 98 149 92
Dasan A M 38 yes no yes Alcoholic 6 8600 107000 1.4 3.8 1.4 1 2 Coarse 9 15.5 13 no 142 99 82.5 42 84.7 44.4
Selvi B F 37 yes no no NASH 8.8 9800 120000 2.4 2.6 1.7 1.3 3 Coarse 8.2 15.5 14.8 Mild 84 102 72 48.8 62 50
Duraipandian B M 59 yes no no Crytogenic 10 4500 100000 3.4 2.5 1.1 1.3 1 Coarse 9 17 14 Moderate 89 79.9 200 92.3 99 56
Ramamurthy B M 55 yes no no Alcoholic 7.8 9000 100000 8 3.3 1.6 1.5 3 Coarse 8.8 15 13.5 Moderate 130 112 166.4 100.6 134.9 95.7
Rangachary B M 50 yes no no Alcoholic 10.3 7500 108000 4.2 2.9 0.9 1.9 3 Coarse 10 12.5 12 Moderate 133.6 134 148.7 117.7 198.7 27.3
Sudhakar B M 32 yes yes no Alcoholic 6.5 6200 67000 2.8 2.2 0.9 1.7 2 Coarse 8 13.5 13 Moderate 50.2 110 120.9 60.1 100.7 62.3
Devagi B F 37 yes no no NASH 8.8 4500 120000 4.2 2.2 1 1.7 4 Coarse 8.2 15.5 14.8 Mild 78 102 72 48.8 62 50
Sudhakar B M 59 no no no Alcoholic 10 11400 100000 3 2.2 1 1.6 3 Coarse 9 17 14 Mild 82 79.9 200 92.3 99 56
Rangarajan B M 55 yes no yes NASH 7.8 5500 100000 6.2 2.7 1.1 2.05 3 Coarse 8.8 15 13.5 Moderate 123 121 166.4 100.6 134.9 95.7
Rangachary B M 50 yes no no Alcoholic 10.3 4400 108000 3.2 2.9 1.1 1.2 2 Coarse 10 12.5 12 Moderate 134 112 148.7 117.7 198.7 27.3
Chinnaswamy B M 32 yes yes yes Biliary 6.5 6200 56000 2.2 2.2 1 1.39 3 Coarse 8 13.5 13 Moderate 57 110 120.9 60.1 100.7 62.3
Srinivasan B M 32 yes yes yes HCV 6.5 3400 56000 2.7 2.2 1 1.39 3 Coarse 8 13.5 13 Moderate 54 110 120.9 60.1 100.7 62.3
Akila B F 37 no no no NASH 8.8 1900 120000 1.9 2.4 1.1 1.4 3 Coarse 8.2 15.5 14.8 mild 84 102 72 48.8 62 50
Arunpandian B M 59 yes no no Crytogenic 10 5500 100000 2.2 2.5 1 1.3 3 Coarse 9 17 14 moderate 89 79.9 200 92.3 99 56
Bimala C F 40 yes no no HBV 7.2 4000 70000 2.3 2.4 1 1.2 3 Coarse 8.8 18.9 13.9 moderate 58 100 95 73 99 61.8
Prabhakar C M 45 yes yes no Biliary 9 1900 78000 12 2 2.1 1.4 4 Coarse a  8 13 14 moderate 60 84.9 72.5 63.5 99 59.2
Saravanan C M 39 yes yes yes NASH 6.6 3400 67000 18.4 2.4 1.1 1.54 3 Coarse 9 18 13.8 Moderate 78 135 238 77.2 247 72
Kuppan C M 48 yes yes yes Autoimmune 6.2 2500 69000 9 2.2 1.9 1.68 3 Coarse 9 14.5 14 massive 63 150 185 80.3 146.5 92.6
Jamuna C F 40 yes no no Alcoholic 12.5 4400 120000 7 2 3.1 1.7 3 Coarse 8 18.5 14 massive 105 120 110 80.6 119 74.5
Vijayakumar C M 60 no yes no Alcoholic 8.6 6400 58000 5.2 2.8 1.7 1.25 3 Coarse 10 16 16 massive 122 106.9 97 102 106 100.2
Saravanan C M 39 yes no yes HBV 6.6 2300 67000 10.4 2.4 1.1 1.54 4 Coarse 10 18 13.8 Moderate 90 145 238 77.2 247 72
Senthil C M 48 yes yes yes Crytogenic 6.2 3500 80000 8 2.2 1.1 1.68 3 Coarse 9 14.5 14 massive 63 150 185 80.3 146.5 92.6
Sarala C F 40 yes no yes NASH 12.5 6000 120000 5.5 2.1 1.5 1.67 4 Coarse 8 18.5 14 massive 67 143 110 80.6 119 74.5
MASTER CHART- CASE (51 patients) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 MASTER CHART- CONTROL (15 patients) 
 
 
 
Name Age Sex Hb WBC Platelet Bilirubin Albumin creatinine INR Liver echo
Liver 
size(cm)
Doppler 
spleen(cm)
Doppler 
PV(mm) ADC liver
ADC 
spleen
Inphase 
liver
Inphase 
Spleen
Opposed 
liver
Oppose
d spleen
Govindaraj 27 M 14 6500 230000 0.9 3.2 0.6 1 Normal 12.9 9 9 324 70.9 221 159 239 161
Krishnan 42 M 13 7500 340000 0.6 3.4 0.7 1 Normal 12.5 8 9 300 72.9 200 159 228 171
Chinnapillai 38 M 16 5500 540000 0.6 3.5 1 1 Normal 14 10 10 350.9 90 192 126 176 151
Ramayee 42 F 13 5000 440000 0.7 3.5 0.6 1.1 Normal 13.5 9 9.2 380.9 89 211 149 180 148
Madhi 22 M 11 4500 430000 0.8 3.5 0.8 1 Normal 12.9 9 9 324 70.9 221 159 239 161
Alagar 34 M 12 6700 250000 0.6 3.7 0.7 1 Normal 12.5 8 9 300 72.9 200 159 228 171
Chinnathai 39 F 12 7300 180000 1 3.4 0.7 1.2 Normal 14 10 10 350.9 90 192 126 176 151
Kuppammal 56 F 12 8400 340000 0.9 3.5 0.8 1 Normal 13.5 9 9.2 380.9 89 211 149 180 148
Venkatesan 54 M 10 7200 280000 0.6 3.5 0.8 1.2 Normal 12.9 9 9 324 70.9 221 159 239 161
Murthi 34 M 10 6500 210000 0.8 3.5 0.9 1 Normal 12.5 8 9 300 72.9 200 159 228 171
Suresh 51 M 11 7800 290000 0.7 3.5 0.9 1 Normal 14 10 10 350.9 90 192 126 176 151
Priya 36 F 9.9 7600 310000 0.8 3.2 0.9 1.1 Normal 13.5 9 9.2 380.9 89 211 149 180 148
Narayanan 59 M 12 8700 300000 0.6 3.4 0.8 1 Normal 12.9 9 9 324 70.9 221 159 239 161
Kala 45 F 12 4500 300000 0.7 3.4 0.8 1 Normal 12.5 8 9 300 72.9 200 159 228 171
Ramalingam 44 M 11 6700 300000 0.8 3.4 0.9 1 Normal 14 10 10 350.9 90 192 126 176 151
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